




Sociedad Española  
de Reumatología -  
Colegio Mexicano  
de Reumatología

# Reumatología Clínica

www.reumatologiaclinica.org



## Special Article

### Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus by the Mexican College of Rheumatology<sup>☆</sup>



Daniel Xibillé-Friedmann,<sup>a</sup> Marcela Pérez-Rodríguez,<sup>b,c</sup> Sandra Carrillo-Vázquez,<sup>d</sup> Everardo Álvarez-Hernández,<sup>e</sup> Francisco Javier Aceves,<sup>f</sup> Mario C. Ocampo-Torres,<sup>g</sup> Conrado García-García,<sup>h</sup> José Luis García-Figueroa,<sup>i</sup> Javier Merayo-Chalico,<sup>j</sup> Ana Barrera-Vargas,<sup>j</sup> Margarita Portela-Hernández,<sup>j</sup> Sandra Sicsik,<sup>k</sup> Lilia Andrade-Ortega,<sup>l</sup> Víctor Manuel Rosales-Don Pablo,<sup>l</sup> Aline Martínez,<sup>m</sup> Pilar Prieto-Seyffert,<sup>n</sup> Mario Pérez-Cristóbal,<sup>j</sup> Miguel Ángel Saavedra,<sup>o</sup> Zully Castro-Colín,<sup>o</sup> Azucena Ramos,<sup>p</sup> Gabriela Huerta-Sil,<sup>q</sup> María Fernanda Hernández-Cabrera,<sup>r</sup> Luis Javier Jara,<sup>c,s</sup> Leonardo Limón-Camacho,<sup>t</sup> Lizbet Tinajero-Nieto,<sup>u</sup> Leonor A. Barile-Fabris<sup>v,\*</sup>

<sup>a</sup> Subdirección de Enseñanza, Investigación y Capacitación, Servicios de Salud de Morelos, Morelos, Mexico

<sup>b</sup> División de Desarrollo de la Investigación, Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social, Mexico City, Mexico

<sup>c</sup> Unidad de Investigación, Colegio Mexicano de Reumatología, Mexico City, Mexico

<sup>d</sup> Servicio de Reumatología, Hospital Regional 1.º de Octubre, ISSSTE, Mexico City, Mexico

<sup>e</sup> Servicio de Reumatología, Hospital General de México, Dr. Eduardo Liceaga, SSA, Mexico City, Mexico

<sup>f</sup> Hospital General Regional 46, Instituto Mexicano del Seguro Social, Guadalajara (Jalisco), Mexico

<sup>g</sup> Servicio de Medicina Interna, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

<sup>h</sup> Centro de Radiodiagnóstico Médico, Villahermosa (Tabasco), Mexico

<sup>i</sup> Instituto Nacional de Nutrición y Ciencias Médicas Salvador Zubirán, Mexico City, Mexico

<sup>j</sup> Servicio de Reumatología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

<sup>k</sup> Hospital de Especialidades, Unidad Médica de Alta Especialidad N.º 71, Instituto Mexicano del Seguro Social, Torreón (Coahuila), Mexico

<sup>l</sup> Servicio de Reumatología, Centro Médico Nacional 20 de Noviembre, ISSSTE, Mexico City, Mexico

<sup>m</sup> Servicio de Reumatología, Instituto Nacional de Cardiología Dr. Ignacio Chávez, Mexico City, Mexico

<sup>n</sup> Centro Médico ABC, Mexico City, Mexico

<sup>o</sup> Servicio de Reumatología, Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico

<sup>p</sup> Centro Médico Nacional del Noreste N.º 25, Instituto Mexicano del Seguro Social, Monterrey (Nuevo León), Mexico

<sup>q</sup> Subdirección, Hospital General de México, Dr. Eduardo Liceaga, SSA, Mexico City, Mexico

<sup>r</sup> Hospital General Regional 220, Instituto Mexicano del Seguro Social, Toluca (Estado de México), Mexico

<sup>s</sup> Dirección de Enseñanza, Hospital de Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico

<sup>t</sup> Hospital Central Norte PEMEX, Mexico City, Mexico

<sup>u</sup> Hospital General Regional N.º 1, Instituto Mexicano del Seguro Social, Santiago de Querétaro, Querétaro, Mexico

<sup>v</sup> Hospital Ángeles del Pedregal, Mexico City, Mexico

## ARTICLE INFO

### Article history:

Received 10 January 2018

Accepted 21 March 2018

Available online 26 December 2018

### Keywords:

Practice guidelines

Systemic lupus erythematosus

Treatment

## ABSTRACT

There are national and international clinical practice guidelines for systemic lupus erythematosus treatment. Nonetheless, most of them are not designed for the Mexican population or are devoted only to the treatment of certain disease manifestations, like lupus nephritis, or are designed for some physiological state like pregnancy. The Mexican College of Rheumatology aimed to create clinical practice guidelines that included the majority of the manifestations of systemic lupus erythematosus, and also incorporated guidelines in controversial situations like vaccination and the perioperative period. The present document introduces the “Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus” proposed by the Mexican College of Rheumatology, which could be useful mostly for non-rheumatologist physicians who need to treat patients with systemic lupus erythematosus without having the appropriate training in the field of rheumatology.

<sup>☆</sup> Please cite this article as: Xibillé-Friedmann D, Pérez-Rodríguez M, Carrillo-Vázquez S, Álvarez-Hernández E, Aceves FJ, Ocampo-Torres MC, et al. Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio Mexicano de Reumatología. Reumatol Clin. 2019;15:3–20.

\* Corresponding author.

E-mail address: [barilita@yahoo.com](mailto:barilita@yahoo.com) (L.A. Barile-Fabris).

In these guidelines, the reader will find recommendations on the management of general, articular, kidney, cardiovascular, pulmonary, neurological, hematologic and gastrointestinal manifestations, and recommendations on vaccination and treatment management during the perioperative period.

© 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

## Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio Mexicano de Reumatología

R E S U M E N

### Palabras clave:

Guía de práctica clínica  
Lupus eritematoso sistémico  
Tratamiento

Existen varias guías de práctica clínica tanto nacionales como internacionales para el tratamiento del lupus eritematoso sistémico. No obstante, la mayoría de las guías disponibles no están diseñadas para población mexicana o solamente son para el manejo de manifestaciones específicas como nefritis lúpica o para algún estado fisiológico como el embarazo. El Colegio Mexicano de Reumatología se propuso elaborar unas guías de práctica clínica que conjuntaran la mayor parte de las manifestaciones de la enfermedad y que incluyeran adicionalmente pautas en situaciones controversiales como lo son la vacunación y el periodo perioperatorio. En el presente documento se presenta la «Guía de práctica clínica para el manejo del lupus eritematoso sistémico» propuesta por el Colegio Mexicano de Reumatología, que puede ser de utilidad principalmente a médicos no reumatólogos que se ven en la necesidad de tratar a pacientes con lupus eritematoso sistémico sin tener la formación de especialistas en reumatología. En esta guía se presentan recomendaciones sobre el manejo de manifestaciones generales, articulares, renales, cardiovasculares, pulmonares, neurológicas, hematológicas, gastrointestinales, respecto a la vacunación y al manejo perioperatorio.

© 2018 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

## Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease that behaves very heterogeneously, and is characterised by remissions and exacerbations. Its incidence and prevalence adjusted by age is 5.5 per 100,000 persons (95% CI: 5.0–6.1) and 72.8 (95% CI: 70.8–74.8).<sup>1</sup> There is no national registry of cases in Mexico but it is known that there are substantial differences in the load of the disease in different populations and countries.<sup>2</sup> For example, the black American population have an incidence and prevalence more than twice that of the Caucasian population.<sup>1</sup> Even among “Hispanic” populations – as Latin Americans are often grouped in clinical studies – there are significant differences in the presentation of the disease.<sup>3</sup>

There are several national and international clinical practice guidelines (CPG) for the treatment of SLE.<sup>4–7</sup> However, the majority of those available are not designed for the Mexican population or only seek to manage specific manifestations, such as lupus nephritis, or physiological conditions, such as pregnancy. National guidelines facilitate the inclusion of certain disease in national health plans. There is no proposal as yet in this country for managing this disease that encompasses representatives of the principal health systems in a global and standardised way.

The disease has distinct features in the different ethnic groups, as reported in cohorts such as LUMINA and GLADEL.<sup>8,9</sup> Mixed race people suffer severe forms, with a higher frequency of glomerulonephritis, higher mortality and accumulated damage. Similarly, some manifestations, such as demyelinating neuropathies and transverse myelitis, are more frequent in Latin American populations, although they usually respond better to treatment than Caucasian populations.<sup>10,11</sup> Some studies have been published on Mexican patients, that assess biochemical variants that might be related to therapeutic response,<sup>12</sup> and specific lupus nephritis induction treatments<sup>13</sup> or specific response to biological drugs.<sup>14</sup> However, these studies have the weakness that they were performed on captive populations, with a limited number of participants, and therefore general peculiarities of Mexican patients or

generalised recommendations cannot be established based on this local evidence.

These facts justify the drawing up of national guidelines in a country where most of the population is of mixed race and requires access to public health systems for medical advice and treatment.

Based on the above, the Mexican College of Rheumatology (MCR) set out to draw up a CPG that would combine the majority of the disease's manifestations, and which would also include guidelines for controversial situations such as vaccination and the perioperative period. Although the recommendations provided in this CPG are based on scientific evidence, all guidelines have limitations in terms of individual decision-making, since each patient has unique features, and therefore this document, as its name states, is only intended as a guide and in no way attempts to substitute or limit the clinical judgement of the physician. Publishing this CPG marks the start of process of continuous updating which the MCR will undertake every 2 years or when appropriate in light of new evidence. The report on the evidence to support the recommendations is being drawn up to complement this guideline, and will be published later.

In preparing this guideline, we endeavoured to cover a wide range of patients. To make the recommendations we took into account publications on patients with SLE, and all organ and systemic involvement, with possible comorbidities. The only two cases that we did not consider were the paediatric population and lupus during pregnancy since the MCR already has a guideline to cover these groups.<sup>5</sup> Because response to treatment and the presentation of the disease can differ in different ethnic groups, the recommendations were made with the Mexican population in mind. The country's socioeconomic context was taken into consideration, because the cost of some drugs can be very high for patients who are not insured or who are not right holders, and for the health institutions themselves. The recommendations included in this guideline, therefore, apply to adult, non-pregnant, Mexican patients with SLE.

This document was undertaken to provide the most complete guideline possible to serve as support particularly for non-rheumatologist doctors who have to treat patients with SLE and lack the training of rheumatology specialists. It is common for

primary care doctors and those of other specialties to have to manage patients with SLE due to the lack of rheumatologists in the health institutions. It is important to stress that patients with SLE should always be treated by rheumatologists, but, where this option does not exist, this guideline can provide useful evidence-based information and serve as support in decision-making in the treatment of these patients. This guideline presents recommendations on the management of general, articular, renal, cardiovascular, pulmonary, neurological, haematological and gastrointestinal manifestations.

## Methodology

The rheumatologists who formed the panel of experts drawing up this CPG were chosen by the governing board of the MCR based on their expertise in the treatment of lupus. Senior rheumatologists from various states of the Mexican Republic were included, and young rheumatologists who had shown great interest in participating in the academic activities of the MCR were invited to form part of the teams.

The panel of experts met for the first time in Mexico City in December 2016 to draft this document. The working groups were formed during this meeting, and the methodology outlined for the preparation of this document. After this meeting, there were 2 face-to-face meetings to check that the proposed methodology was being followed, and the findings from the literature were presented by each of the teams. In addition, there was constant electronic communication. The teams, after presenting their results to the other panellists, prepared their recommendations and sent them to the methodologist coordinating the work, who in turn drafted a document with all the recommendations. This document was submitted electronically to all the panellists for their consideration, and the final recommendations were chosen by consensus: there was no disagreement between the team members.

The author responsible for publication submitted the subjects that the guideline needed to cover to the Research Committee, and together they made the final decision to produce recommendations per type of manifestation, and include recommendations on general management.

## Literature Search

For the literature search, a series of research questions were generated for the general management of the disease, and for each of its manifestations. Each research question resulted in one or more than one search, depending on its complexity. The PICO methodology was used, for searches clearly identifying the population (P), intervention (I), comparator (C), and outcome (O). In sum, the target population were patients with SLE, the interventions and comparators were all the treatments presented in this document, and there were multiple outcomes. Not only were the most clinically relevant outcomes considered, such as prevention of renal damage or reducing progression of the disease, remission after induction, prevention of relapse, the control or reduction of the manifestations of the disease, but also those relevant to the patients, such as fatigue and pain reduction. The searches were performed from 2000 to 2016, they were limited to adults and, given the limited scientific literature, the search was not restricted to publications on Mexican populations, although the articles that did cover this population bore more weight when making the recommendations. Given the absence of direct evidence, most of the recommendations were made based on the results from other populations.

Each team received from the methodologist the PICO search mechanisms for the subject that they had been allocated. Each team reviewed the articles and, based on the review of related articles

and the references cited in the publications of interest, completed their search. The team members checked that the articles that were to be used to make the recommendations answered the research questions, and met the selection criteria that had been determined beforehand by the governing board of the MCR. Any disagreements among the teams were resolved through discussion between team members. Once all the scientific literature had been reviewed, the recommendations were drafted. Unlike most Mexican CPG that use the levels of evidence of Shekelle et al.,<sup>15</sup> the GRADE<sup>16</sup> system was used to draw up the recommendations of this CPG, and rate the level of evidence and strength of the recommendations. This is the system currently recommended by the same authors who developed the levels of evidence used in previous years in the new guideline for drawing up CPG.<sup>17</sup> The GRADE method has proved superior to other systems for evaluating CPG<sup>18</sup> recommendations, and has now been adopted by the Cochrane Collaboration.

## Quality of the Evidence

The quality of the body of the evidence used to make the recommendations was classified as very low, low, moderate and high, depending on its characteristics. Expert opinion was not considered evidence; therefore it was classified as very low quality of evidence. A classification of high quality means that further research is very unlikely to change confidence in the estimate of effect, moderate quality means that that further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate; low quality means that further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate and, finally, very low quality means that any estimate of effect is very uncertain.<sup>19</sup>

## Strong or Weak Recommendation or Good Practice Recommendation

Once the quality of the evidence had been assessed, the recommendations were determined as either strong or weak. It is said that when a strong recommendation is made, the desirable consequences of the intervention clearly outweigh the undesirable consequences; by contrast, with weak recommendations it is uncertain whether the desirable consequences substantially outweigh the undesirable consequences or are similar.<sup>19</sup> The recommendations that were considered important but that could not be rated in terms of quality of evidence or strength of recommendation were classified as “good practice”.<sup>20</sup>

## Results and Discussion

### Treatment of Systemic Lupus Erythematosus

There is no general treatment for SLE because of the heterogeneity of its behaviour, and its management must be individualised based on patient features and the activity of the disease, and even with the possibility of access to certain drugs, such as the biological therapies. Treatment is based on the use of glucocorticoids (GC), nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials and various immunosuppressants. The prognosis of these patients has notably improved with these treatments, although there can be frequent relapses as well as, in some cases, therapeutic failure. The toxicity of these drugs must be monitored. The aim of treatment is to achieve remission<sup>21</sup> (absence of perceived clinical activity) or, at least, achieve minimum disease activity<sup>22,23</sup> for the patient enabling immunosuppressants and GC to be stopped or at least maintained at the lowest possible doses to prevent their associated adverse effects. There are patients who are refractory to treatment, do not respond to standard treatment or require an unacceptable

dose of GC to maintain remission.<sup>24</sup> Before a patient refractory is considered refractory, their adherence to the therapy should be checked, as well as any accumulated damage that is not likely to improve with treatment.<sup>25,26</sup>

For the purposes of these recommendations, severe lupus is understood to be when treatment is needed for potentially fatal manifestations such as lupus nephritis, neuropsychiatric involvement, haemolytic anaemia (Hb < 7 g/dL), thrombocytopenia (< 30,000 platelets),<sup>27</sup> vasculitis, pulmonary haemorrhage, myocarditis, lupus pneumonitis, severe myositis, lupus enteritis, lupus pancreatitis, lupus hepatitis, protein-losing enteropathy, severe keratitis, retinal vasculitis, severe scleritis, optic neuritis. Non-severe lupus is understood as the involvement of a minor organ (mucocutaneous, articular, serous lupus), and when the manifestations of the disease do not warrant treatment.<sup>28</sup>

As we have already mentioned, treatment of SLE must be individual and will depend on the type of manifestation, the organ/s or system/s involved, and the severity of the disease.<sup>26</sup> Classification of the manifestations according to severity are given in [Table 1](#).

### General Considerations on the Use of Drugs

The evidence-based recommendations for each type of manifestation that form part of this CPG for the management of SLE are found in the tables of recommendations for each manifestation. In addition, the section below and [Table 2](#) present some generalities regarding the drug groups most used in the treatment of SLE.

**Table 2**  
General Considerations on the Use of Drugs for the Treatment of SLE.

Drug	Indication according to severity			Indications according to manifestation	Safety recommendations
	Mild	Moderate	Severe		
Glucocorticoids	X	X	X	Generalised used according to the type and severity of the manifestation	Metabolic monitoring of the patient, blood pressure and weight
Chloroquine	X	X		Musculo-skeletal, skin, cardiovascular, kidney (to maintain remission), haematological	Annual visit to the ophthalmologist
Hydroxychloroquine	X	X		Musculo-skeletal, skin, cardiovascular, kidney (to maintain remission), haematological	Annual visit to the ophthalmologist
Azathioprine		X	X	Haematological, cardiovascular, kidney, gastrointestinal	Monitor haematic cytometry
Methotrexate	X	X		Musculo-skeletal	Monitor liver and kidney function
Leflunomide	X	X		Musculo-skeletal	Monitor liver and kidney function
Mycophenolate mofetil/mycophenolic acid Cyclophosphamide	X	X	X	Kidney, haematological, cardiopulmonary, gastrointestinal	Do not use during pregnancy
Cyclosporine		X	X	Musculo-skeletal, kidney, haematological, cardiopulmonary, neurological	Use with care in people of reproductive age due to association with gonadal dysfunction; do not use during pregnancy, monitor haematic cytometry
Belimumab	X	X		Kidney, haematological	Monitor blood pressure and kidney function
Rituximab			X	Musculo-skeletal, skin, general manifestations	Monitor in patients with depression or suicidal ideation; monitor associated infections
Immunoglobulin			X	Manifestations that are refractory to treatment	Monitor associated infections; monitor allergic reactions during administration
				Manifestations that are refractory to treatment	Monitor blood pressure; monitor allergic reactions to administration

**Table 1**  
Classification of Clinical Manifestations in SLE Based on Their Impact on Patients.<sup>25,26</sup>

Minor manifestations	Moderate manifestations	Severe manifestations
<ul style="list-style-type: none"> <li>– Are not function or life-threatening</li> <li>– Do not cause irreversible damage or any relevant sequelae (e.g., fatigue, fever, arthralgia, mild or intermittent arthritis, some skin manifestations and mild serositis)</li> <li>– Can be treated with NSAIDs, antimalarials and GC at low doses (<a href="#">Table 3</a>)</li> </ul>	<ul style="list-style-type: none"> <li>– Are not life-threatening, but do cause functional limitation (e.g., persistent arthritis, severe or extensive skin lesions, mild thrombocytopenia and moderate serositis)</li> <li>– Can be treated with GC at low to medium doses, antimalarials and oral immunosuppressants such as methotrexate, leflunomide and azathioprine (<a href="#">Table 3</a>)</li> </ul>	<ul style="list-style-type: none"> <li>– Affect a major organ and are life or function-threatening</li> <li>– Have a risk of chronic damage with major organic sequelae (e.g., lupus glomerulonephritis, severe neurological involvement, pulmonary haemorrhage, vasculitis, bullous lupus, etc. These manifestations can be treated with GC at high doses or with pulses of cyclophosphamide or mycophenolic acid or other immunosuppressants)</li> </ul>

### Glucocorticoids

GC are the cornerstone of treatment for SLE. It is common for GC pulses to be administered that, for the purposes of this document

**Table 3**

Considerations on the Use of Glucocorticoids in the Remission Induction and Maintenance Regimen for SLE.

Remission induction	Maintenance
The initial dose of GC (prednisone or equivalent) depends on the activity of the SLE – Low activity: low doses (<7.5 mg/day) – Moderate activity: intermediate doses (7.5–30 mg/day) – Severe activity: high doses (30–100 mg/day or pulses with doses >250 mg/day, usually intravenous for 1–5 days) <sup>45,46</sup>	Once reduction of activity or remission has been achieved, start tapering regimen. Usually started after 6 weeks of high doses <sup>a</sup> – Reduce 10%–20% every 7–15 days until 30 mg/day – Then, reduce 10% every 15 days until discontinued or continue with maintenance dose (<7.5 mg/day) <sup>29,46</sup>

<sup>a</sup> There is no standardised regimen.

and unless otherwise specified, will be defined as the intravenous administration of high doses of steroids. Generally 1 g of methylprednisolone succinate is administered over a period of 2 h; an average of 3 pulses is given, one per day, for 3 consecutive days. Although there is no consensus on standardised recommendations, comorbidities and risk factors for adverse events should be assessed in patients treated with GC, and treated if appropriate. During treatment the patient's body weight, blood pressure, peripheral oedema, heart failure, serum lipids and glucose must be monitored, and they must undergo an ophthalmological assessment. If the patient has a dose >75 mg/day of prednisone and requires treatment for more than 3 months, a calcium and vitamin D supplement should be started. The use of antiresorptive agents must be assessed based on the patient's risk factors.<sup>29</sup> Considerations on their use in the remission induction and maintenance schemes are shown in Table 3.

### Antimalarials

Antimalarials have been used in the treatment of SLE since the nineteenth century and, although there are few studies that aim to demonstrate their efficacy, the current evidence suggests the use of hydroxychloroquine (HCQ) (at 20–400 mg/day) or chloroquine (at 150–300 mg/day). There is no evidence that higher doses are more effective than low doses, and the appropriate dose must be left to the judgement of the clinician. Antimalarials have photoprotective, lipid lowering, antiangiogenic, antithrombotic effects, and also inhibit the function of the B cell-activating factor and phospholipase A2-activating factor, which means that they are indicated in the treatment of skin lupus, of SLE with mild to moderate activity, as concomitant treatment to prevent relapses and damage to major organs.<sup>30</sup> Provided there are no contradictions, antimalarials are recommended for all patients with SLE. HCQ is associated with longer damage-free survival than when it is not used (45.1% vs 26.5%;  $P < .001$ ), and correlates negatively with accumulated damage measured by SLICC ( $r = -.22$ ;  $P = .015$ ),<sup>31</sup> reducing the probability of accumulated renal damage (HR .68; 95% CI: .53–.93)<sup>32</sup> (OR .38; 95% CI: .25–.58)<sup>33</sup> in those who use them compared to those who do not. They are also useful in the prevention of morbidity due to atherosclerosis, and in the management of antiphospholipid antibody syndrome associated with SLE.<sup>34,35</sup> Discontinuing HCQ has been reported to increase the relative risk of relapse by 2.5 (95% CI: 1.08–5.58) over a period of 6 months.<sup>36</sup> A baseline and subsequent annual ophthalmological assessment should be performed to monitor adverse events.

### Non-steroidal Anti-inflammatory Drugs

NSAIDs are recommended in rheumatic diseases for treating pain and inflammation. The consensus on the use of NSAIDs of the Spanish Rheumatology Society and the MCR recommends individualising their use based on each patient's variability of response, gastrointestinal toxicity, cardiovascular, renal and hepatic risk factors. One NSAID cannot be considered better than another (traditional or COXIBS). Simultaneous use of more than one NSAID must be avoided, since this only increases toxicity, and does not increase efficacy (ceiling effect). In acute processes, they should be used for the shortest possible time at the maximum recommended dose, and in chronic processes, the minimum dose necessary to maintain the desired clinical response should be used. Risk factors, adverse effects and indication for use should be assessed periodically. Concomitant use with GC increases gastrointestinal toxicity. Interactions with other drugs such as antihypertensives, glucose-lowering drugs, oral anticoagulants, etc. should be assessed.<sup>37</sup>

### Immunosuppressants

Most rheumatologists agree on the use of immunomodulators for moderate to severe SLE during an intense period of immunosuppression known as induction therapy, followed by a longer period of maintenance therapy. The three main objectives of induction therapy are to halt damage, recover function, and control immunological activity. Maintenance therapy is used to consolidate remission and prevent relapse with a treatment programme with a low risk of complications and more convenient for the patient, under the current concept of "personalised treatment". The drugs that are traditionally used with these aims are the following:

- Mycophenolic acid (MMF): the dose varies widely depending on the organ involved and the severity of the manifestation; it can range from 1 to 3 g. Adverse events that must be monitored are cytopenia, altered LFT, diarrhoea and teratogenicity.<sup>38–41</sup>
- Cyclophosphamide (CYC): the dose can vary from 500 to 1000 mg/m<sup>2</sup> of body surface area. Adverse events that must be monitored are cytopenia, teratogenicity, infertility, myeloproliferative disorders, haemorrhagic cystitis, and bladder cancer.<sup>40</sup>
- Azathioprine: the dose varies between 1 and 3 mg/kg/day and the adverse events to be monitored are myelosuppression, hepatotoxicity, lymphoproliferative disorders and teratogenicity.<sup>41,42</sup>
- Methotrexate: can be used in doses from 7.5 to 25 mg, orally or parenterally, and the adverse events to be monitored are myelosuppression, hepatotoxicity, pneumonitis, alopecia, stomatitis, and teratogenicity.<sup>39–42</sup>
- Cyclosporine: principally used in resistant nephropathy, and the main adverse events are gingival hyperplasia, high blood pressure, hirsutism, renal failure, and anaemia.<sup>43</sup>

Other drugs used in SLE are the biologics belimumab and rituximab. Belimumab is used in mild to moderate manifestations such as arthritis, serositis or if there is a skin infection (dsDNA+ or C3/C4 consumption). B-lymphocyte depletion is the most common adverse event with this biologic. Rituximab is also used when there is joint involvement resistant to conventional treatment, haematological involvement, involvement of the central nervous system or resistant nephritis, and the principal adverse events are allergy, serum sickness, and progressive multifocal leukoencephalopathy.<sup>44</sup>

### Recommendations Based on the Review of the Scientific Evidence

The tables below show the recommendations resulting from the literature review and the work by consensus of the participants

**Table 4**

Recommendations for the Management of the General Manifestations of SLE.

*Fatigue, pain and fever*

- Dehydroepiandrosterone or fish oil are not suggested for the management of fatigue.<sup>47–49</sup> (Moderate quality of evidence, weak recommendation)
- Cholecalciferol 50,000 IU/week could be considered for the management of fatigue.<sup>50</sup> (Moderate quality of evidence, weak recommendation)
- Due to their cost, abatacept, belimumab or rituximab should not be considered for use in first-line management of fatigue.<sup>51–56</sup> (High quality of evidence, strong recommendation)
- There is insufficient evidence to recommend the use of acupuncture, phototherapy, psychological approach or diet in treating the pain and fatigue experienced by people with SLE.<sup>48,49,57</sup> (Low quality of evidence, weak recommendation)
- Both aerobic and isotonic exercise for at least 15 min, 3 times a week, is useful in reducing fatigue (measured by the FSS) in SLE with no disease activity.<sup>48,58,59</sup> (Moderate quality of evidence, strong recommendation)

*Differential diagnosis of fever*

- First infection and the toxic effect of drugs must be ruled out, respectively, before attributing the manifestation to disease activity. To determine whether the fever is associated with the activity of SLE it should be borne in mind that fever due to activity is usually coincident with low complement levels, raised anti-DNA counts, and slightly raised CRP.<sup>57</sup> (Moderate quality of evidence, strong recommendation). In patients with no initial signs of infectious process, medium to high doses of GC are recommended (prednisone at 20–40 mg/day with a response in 1–5 days); if there has been no response within 72 h, consider a different aetiology.<sup>59,60</sup> (Moderate quality of evidence, strong recommendation)

*Biopsy*

- Whenever possible and if there is no formal contraindication, a biopsy should be performed on patients with signs suggestive of lupus nephritis to classify the type of glomerulonephritis, and to evaluate signs of activity, chronicity, vascular and tubular changes.<sup>7,61,62</sup> (High quality of evidence, strong recommendation)
- In the event of relapse where a change to nephritis is suspected or scarring nephropathy, a repeat biopsy should be considered.<sup>7,63,64</sup> (Moderate quality of evidence, weak recommendation)

*Vaccination*

- It is recommended that vaccinations given to patients diagnosed with SLE and, if possible, the date they were given, should be recorded at the time of the patient's first contact with the rheumatology specialist. (Good practice)
- It is recommended that degree of disease activity should be established using the SLEDAI (Systemic Lupus Erythematosus Activity Index), as well as the current immunosuppressant treatment. (Good practice)
- In patients with SLE who are vaccinated, it is recommended that events appearing within the first 48 h temporarily associated with the vaccination should be monitored, such as hyperthermia, erythema and pain at the injection site.<sup>65</sup> (Low quality of evidence, strong recommendation)
- Both seasonal and epidemic influenza vaccinations are recommended:
- For patients with SLE in remission (SLEDAI 0) or with mild (SLEDAI 2–4) to moderate activity (SLEDAI 4–8).<sup>66–80</sup> (High quality of evidence, strong recommendation)
- When the equivalent dose of prednisone is less than 20 mg/day.<sup>69</sup> (Moderate quality of evidence, strong recommendation)
- For patients with SLE treated with MMF, methotrexate, azathioprine or CYC, even if these patients have a lesser response.<sup>69,72,73,76</sup> (Moderate quality of evidence, strong recommendation)
- It is recommended that the 23-valent pneumococcal vaccine should be given to patients with SLE in remission or with mild to moderate disease activity.<sup>78,81–84</sup> (High quality of evidence, strong evidence)
- It is suggested that the quadrivalent human papilloma virus vaccine should be given to patients with SLE:
- Who are under the age of 25, with no history of thrombophilia or other risk factors for thrombosis (immobility, smoking, use of hormonal drugs).<sup>85</sup> (Moderate quality of evidence, weak recommendation)
- With doses of prednisone under 10 mg/day.<sup>85,86</sup> (Moderate quality of evidence, weak recommendation)
- With immunosuppressants (MMF), even though these patients might have a lesser response.<sup>85</sup> (Moderate quality of evidence, weak recommendation)
- The hepatitis B vaccine and booster vaccine are recommended for patients with SLE in remission, and with mild (SLEDAI 2–4) to moderate (SLEDAI 4–8) activity.<sup>87</sup> (Moderate quality of evidence, strong recommendation)
- The tetanus and *Haemophilus influenzae* B vaccine and their boosters are recommended for patients with SLE:
- In remission, mild (SLEDAI 2–4) to severe (SLEDAI >8) activity.<sup>77,78</sup> (Moderate quality of evidence, strong recommendation)
- Receiving treatment with methotrexate, azathioprine or CYC, although these patients can have a lesser response.<sup>78</sup> (Moderate quality of evidence, weak recommendation)
- Live attenuated virus vaccinations are not recommended, such as the herpes zoster vaccine, for patients with SLE with disease activity.<sup>88,89</sup> (Low quality of evidence, weak recommendation)

Table 4 (Continued)

*Perioperative recommendations*

- For patients scheduled for orthopaedic surgery or other types of surgery with similar risk such as laparoscopy (fundoplication, appendectomy, cholecystectomy) the following is recommended<sup>90-92</sup> (moderate quality of evidence, strong recommendation):
- An SLEDAI score prior to surgery of between 0 and 3 in order to proceed with surgery.
- Patients with a surgical risk, ASA score of IV or V, should not be operated until their general condition improves.
- Before undergoing surgery, patients with SLE should have negative urine and oropharyngeal cultures with no symptoms or signs of active infection.
- It is suggested that NSAIDs should be discontinued at least 3 to 4 times their half life or 2–3 days before orthopaedic surgery (especially surgery involving the tendons and soft tissues) and restarted only when wound healing has taken place (6 weeks at least).<sup>93</sup> (Low quality of evidence, weak recommendation)
- Patients receiving treatment with GC who are to be operated, should be given the following according to the type of surgery they are to undergo<sup>94</sup> (low quality of evidence, weak recommendation):
- 25 mg hydrocortisone (or the equivalent dose of GC), a single dose on the day of surgery for minor surgery (abdominal wall plasty, colonoscopy, for example)
- From 50 to 75 mg of hydrocortisone (or the equivalent dose of GC) on the day of surgery and at 24 h resume the usual dose for moderate surgery (cholecystectomy, hemicolectomy)
- From 100 to 150 mg of hydrocortisone (or the equivalent dose of GC) on the day of surgery and resume the usual dose at 24 h for major surgery (major cardiothoracic surgery, Whipple's procedure)
- It is recommended that haemostasis-altering drugs should be managed as follows<sup>95-97</sup> (moderate quality of evidence, weak recommendation):
- Acetylsalicylic acid and clopidogrel: suspend 7 days before surgery and restart 24–48 h after the event
- Dipyridamole: suspend from 7 to 14 days before surgery
- Direct-Acting Oral Anticoagulants (DOACs) (rivaroxaban, dabigatran and apixaban): suspend from 24 h to 48 h before surgery
- Unfractionated heparin: suspend from 4 h to 6 h prior to surgery
- Low-molecular weight heparin: suspend at least 12–18 h prior to the surgical event, and restart 48 h to 72 h after it
- Warfarin: suspend 5 days before surgery. For elective surgery, it is recommended that patients using warfarin should have an international normalized ratio less than 1.5, with an international normalized ratio (INR) of over 1.8 it is recommended that 1 mg vitamin K should be administered intravenously.<sup>95-97</sup> (Moderate quality of evidence, weak recommendation)
- In the event of emergency surgery give 5 mg of vitamin K intravenously or fresh frozen plasma, start with 2 units of Prothrombinex-HT.<sup>95-97</sup> (Moderate quality of evidence, weak recommendation)
- For patients who are not taking anticoagulant medication and who require major surgery, thromboprophylaxis with low molecular weight heparin is suggested 12 h before surgery and extended to 35 days after it.<sup>95-97</sup> (Moderate quality of evidence, weak recommendation)
- For patients with severe lupus undergoing orthopaedic surgery (such as to the hip or knee) it is recommended that the current doses of MMF, azathioprine, cyclosporine and tacrolimus should be continued.<sup>98</sup> (Low quality of evidence, weak recommendation)
- For patients with non-severe lupus undergoing orthopaedic surgery (such as to the hip or knee), it is recommended that MMF, azathioprine, cyclosporine and tacrolimus should be suspended one week before the surgery, and resumed 5 days after it if there is no infection or complication in wound healing.<sup>98,99</sup> (Low quality of evidence, weak recommendation)
- It is recommended that current doses of methotrexate, HCQ, antimalarials, sulfasalazine should be continued during the perioperative period.<sup>98,99</sup> (Low quality of evidence, weak recommendation)
- For hip surgery, it is recommended that broad spectrum antibiotics at conventional doses should be given one day before surgery, and continued from 5 to 7 days after it.<sup>92</sup> (Low quality of evidence, weak recommendation)
- For patients using rituximab, it is recommended that surgery should be scheduled for month 7 after it has been given.<sup>99</sup> (Low quality of evidence, weak recommendation)
- For patients using belimumab, it is recommended that surgery should be scheduled in week 5 after it has been given.<sup>99</sup> (Low quality of evidence, weak recommendation)

**Table 5**  
Recommendations for Renal Manifestations.

*Nephritis in Mexican patients (Latin and Central Americans)*

– Remission induction treatment with MMF (2–3 g/day) or CYC (1 g/m<sup>2</sup> of body surface area per month)<sup>100,101</sup> is recommended for this population. (Moderate quality of evidence, strong recommendation)

*Nephritis I and II*

– Treatment with immunosuppressants is recommended for nephritis I and II with impaired kidney function, active sediment or proteinuria  $\geq$  1 g/day.<sup>102–104</sup> (Low quality of evidence, weak recommendation)  
– For the treatment of nephritis I or II, evaluating toxicity/benefit, azathioprine (from 1 to 2 mg/kg/day), MMF (from 1 to 2 g/day) or CYC (from .750 to 1 g/m<sup>2</sup> of body surface area per month) combined with GC, at medium doses (.5 g/kg prednisone) with gradual tapering, for a minimum period of 6 months.<sup>103</sup> (Low quality of evidence, weak recommendation)

*Induction treatment for nephritis III/IV and V with proliferative component*

– Patients with nephritis class III/IV and V with a proliferative component require a remission induction treatment regimen which could comprise MMF (2–3 g/day) or CYC (monthly pulses of 1 g/m<sup>2</sup> of body surface area or reduced dose according to Euro-Lupus), combined with gradual tapering of steroids, for a minimum period of 6 months.<sup>105–108</sup> (High quality of evidence, strong recommendation)  
– If there is no response to these regimens, rituximab, tacrolimus, azathioprine or combined therapy with different therapeutic targets are recommended.<sup>107,109–113</sup> (Moderate quality of evidence, strong recommendation)  
– GC should be used in pulses (1 g methylprednisolone for 3 days) or orally (from .5 to 1 g/kg of prednisone) as concomitant initial treatment, with gradual tapering.<sup>7</sup> (Moderate quality of evidence, strong recommendation)

*Class V nephritis with no proliferative component*

– MMF should be considered (from 2 to 3 g/day) or azathioprine (from 1 to 3 mg/kg).<sup>100,112,115</sup> (High quality of evidence, strong recommendation)  
– Tacrolimus, cyclosporine A, cyclophosphamide or rituximab could be considered for patients who are refractory to treatment.<sup>110,116,117</sup> (Moderate quality of evidence, weak recommendation)

*Maintenance therapy for nephritis III/IV and V with proliferative component*

– MMF should be considered (from 2 to 3 g/day) or azathioprine (from 1 to 3 mg/kg/day) long term (a minimum follow-up of 18 months).<sup>114,118,119</sup> (High quality of evidence, strong recommendation)  
– For patients who are intolerant to MMF or azathioprine, quarterly CYC, tacrolimus, cyclosporine A or rituximab could be considered.<sup>110</sup> (Moderate quality of evidence, weak recommendation)

*Rapidly progressive nephritis/with cellular crescents*

– Induction management with CYC 750 mg to 1 g/m<sup>2</sup> of body surface area monthly is recommended, or, MMF (from 2 to 3 g/day for 6 months). Both options with administration of pulses of methylprednisone 1 g/day for 3 days or prednisone at high doses (1 g/kg/day with gradual tapering according to outcome).<sup>120,121</sup> (Moderate quality of evidence, strong recommendation)  
– Tacrolimus is recommended at doses of .1–.15 mg/kg/day orally in two divided doses, titrated to maintain minimum levels of 6 to 8 ng/ml for 12 h, and should be considered as an alternative induction treatment to iv CF or MMF.<sup>121</sup> (Moderate quality of evidence, strong recommendation)  
– Rituximab could be considered<sup>122,123</sup> or multitarget therapy<sup>124</sup> for the management of refractory cases, assessing risk over benefit. (Low quality of evidence, weak recommendation).  
– Maintenance treatment can be with MMF (from 2 to 3 g/day), azathioprine (from 2 to 3 mg/kg/day) and prednisone at a tapering dose.<sup>114</sup> (Low quality of evidence, strong recommendation)

*Adjuvant management*

– Weight control is recommended for obese patients, because of the benefits in preventing progression of kidney disease and controlling blood pressure.<sup>125</sup> (High quality of evidence, strong recommendation)  
– ACE-I and AIIIRA are recommended as antiproteinuric agents.<sup>125,126</sup> (High quality of evidence, strong recommendation)  
– Strict control of blood pressure with goals at lower than 130/80 mmHg, and control of other cardiovascular risk factors such as smoking.<sup>125,127</sup> (High quality of evidence, strong recommendation)  
– Control of dyslipidaemia is recommended, with goals of LDL cholesterol <100 mg/dl and triglycerides <150 mg/dl.<sup>125</sup> (Moderate quality of evidence, strong recommendation)  
– Permanent HCQ 5 mg/kg/day is recommended to reduce the likelihood of renal relapse,<sup>128–130</sup> and for its benefits on dyslipidaemia.<sup>131</sup> (High quality of evidence, strong recommendation)

*Periodic monitoring of response*

– Monitoring of the response to treatment of lupus nephritis should be individualised, and urinary sediment, 24 h urine protein or PR/Cr ratio, serum creatinine, complement and anti-DsDNA tests are accepted as the most useful tools to that end.<sup>103,125</sup> (High quality of evidence, strong recommendation)  
– Monthly monitoring is recommended during the remission induction period, and quarterly for maintenance.<sup>103,132</sup> (High quality of evidence, strong recommendation)

*Treatment of relapses*

– It is recommended that remission induction treatment that has previously been effective should be repeated.<sup>125</sup> (Moderate quality of evidence, strong recommendation)

*Management with renal replacement therapy and transplantation*

– For patients with chronic kidney failure due to lupus nephritis, renal transplantation is recommended as the best option for long-term treatment.<sup>133</sup> (High quality of evidence, strong recommendation)  
– Haemodialysis is recommended as the first replacement therapy option for patients in chronic kidney failure due to lupus nephritis, since peritoneal dialysis has been associated with a greater number of complications, and mortality due to immunosuppressants.<sup>134</sup> (Moderate quality of evidence, strong recommendation)

*Lupus nephritis in patients wanting to become pregnant*

– It is recommended that all women desiring pregnancy should have been in remission from the disease for at least 6 months before conception.<sup>135</sup> (High quality of evidence, strong recommendation)  
– Pregnancy is not recommended if creatinine levels exceed 2.8 mg/dl or there is clear evidence of disease activity.<sup>136</sup> (High quality of evidence, strong recommendation)  
– For patients with lupus nephritis we recommend a change of immunosuppressant medication and antihypertensives to those allowed in pregnancy to maintain remission, and to prevent relapse.<sup>5,137</sup> (High quality of evidence, strong recommendation)



**Table 6**  
Recommendations for Cardiovascular Manifestations.**Pericarditis**

- NSAIDs: in cases of mild, acute or chronic pericarditis, with or without effusion, aspirin (500 mg orally every 12 h) is recommended or indomethacine (50 mg every 12 h orally) or ibuprofen (600 mg every 8 h orally) until there is improvement in clinical symptoms.<sup>26,138</sup> (Low quality of evidence, weak recommendation)
- Glucocorticoids: in the case of acute or chronic pericarditis with pericardial effusion, prednisone (.5 mg/kg/day) is recommended for patients whose initial manifestation is mild to moderate pericarditis. In the case of severe or constrictive pericarditis, methylprednisolone pulses (1 g/day for 3 days) are recommended.<sup>139–143</sup> (Moderate quality of evidence, strong recommendation)
- Colchicine: for patients with recurrent pericarditis or recent onset pericarditis, 1 mg colchicine is recommended in combination with conventional treatment with steroids and immunosuppressants until remission is achieved. In order to avoid relapse of pericarditis, the addition of colchicine (1 mg/day for at least one month) is recommended.<sup>140,144,145</sup> (Moderate quality of evidence, weak recommendation)
- Surgery: surgery for pericarditis is recommended for pericarditis that is resistant to treatment or tamponade that does not respond to pharmacological treatment. (Good practice)

**Myocarditis**

- Steroids: pulses of GC are recommended, methylprednisolone (1 g/day for 3 days) for cases of severe myocarditis with arrhythmia, ventricular ejection fraction <55%, and the administration of prednisone (from .5 to 1 mg/kg/day) after pulse administration.<sup>146</sup> (Low quality of evidence, strong recommendation)
- Antimalarials: HCQ at doses of 200–400 mg/day, or chloroquine (from 150 to 300 mg/day) for the maintenance stage are recommended.<sup>146</sup> (Low quality of evidence, weak recommendation)
- Cyclophosphamide: in the case of severe manifestation with arrhythmia or ventricular ejection fraction of less than 40%, the use of intravenous CYC at doses of .5–1 g/m<sup>2</sup> of body surface area is recommended for 3–10 months as first line treatment together with steroids.<sup>147</sup> Based on the experience of the panel of experts, it is recommended that it should be administered for at least 3 months awaiting a response; if there is no response, discontinue to prevent the risk of toxicity, and if there is a response, a minimum of 6 months' treatment is recommended. (Moderate quality of evidence, strong recommendation)
- Mycophenolic acid: MMF is recommended at doses of 2 g/day in divided doses, as maintenance therapy after intravenous CYC, to reduce relapses.<sup>146</sup> (Moderate quality of evidence, weak recommendation)
- Azathioprine: Azathioprine (from 2 to 3 mg/kg/day) is recommended as maintenance therapy after CYC in patients who are intolerant to MMF<sup>146</sup> and cytopenias should be monitored (HB). (Low quality of evidence, weak recommendation)
- Gammaglobulin: in the case of complicated myocarditis, gammaglobulin at doses of 400 mg/kg/day for 5 days is recommended for patients for whom standard induction therapy with oral or intravenous steroids and CYC has failed.<sup>146</sup> The onset of hypertension during infusion, as well as anaphylactic reactions, should be considered. (Low quality of evidence, weak recommendation)

**Pulmonary hypertension**

- Steroids: GC at doses of .5 at 1 mg/kg/day for 4 weeks with gradual tapering to minimum doses of 5 mg daily for maintenance or until discontinued.<sup>148,149</sup> (Moderate quality of evidence, strong recommendation). The use of methylprednisolone pulses at doses of 1 g/day for 3 days was suggested for severe cases when they coincide with the involvement of other organs and relapses.<sup>150,151</sup> (Low quality of evidence, strong recommendation)
- Cyclophosphamide: it is recommended that CYC is used at doses of 600 mg/m<sup>2</sup> of body surface area for 3–6 months as immunosuppressant treatment combined with GC, vasodilators, diuretics, and other support means.<sup>150,152</sup> Other regimens suggested were 500–1000 mg/m<sup>2</sup> of body surface area monthly for 3–6 months.<sup>149</sup> (Moderate quality of evidence, strong recommendation)
- Mycophenolic acid: MMF (from 2 to 3 g/day) is recommended as maintenance after CYC or in the case of intolerance or if IV CYC is contraindicated.<sup>151</sup> (Low quality of evidence, weak recommendation)
- Calcium channel blockers: calcium channel blockers cannot be recommended because there is insufficient evidence regarding their efficacy and safety in pulmonary hypertension associated with SLE.<sup>153,154</sup> (Low quality of evidence, weak recommendation)
- Prostanoids: For patients with NYHA functional class III and IV, the use of epoprostenol is recommended administered intravenously by central venous catheter with continuous infusion pump at doses of 2–40 ng/kg/min for 3–6 months, starting with 2–4 ng/kg min, and gradually increasing the dose.<sup>153–156</sup> (High quality of evidence, strong recommendation). Treprostinil is recommended at doses of 1.25–2.5 ng/kg/min intravenously by continuous infusion pump increasing by 1.25–2.5 mg every 1–2 weeks, to a maximum dose of 22.5 ng/kg/min for 12 weeks for patients with SLE, and NYHA functional class III and IV.<sup>153,154,157</sup> (Moderate quality of evidence, weak recommendation).
- Endothelin receptor antagonists: bosentan is recommended at doses of 62.5 mg twice daily for 4 weeks with follow-up 125 mg twice daily for 3–12 months combined with GC and immunosuppressants as first line management for patients with NYHA functional class II and III.<sup>153,158,159</sup> (High quality of evidence, strong recommendation). Sitaxentan and ambisentan are not recommended since there is no evidence of their efficacy and safety in the management of PHT in SLE.<sup>153</sup> (High quality of evidence, strong recommendation).
- Phosphodiesterase inhibitors (PDE-5)<sup>a</sup>: Sildenafil is recommended at initial doses of 20 mg, 3 times a day; it can be gradually increased to 80 mg, 3 times a day, as tolerated by the patient for better results long term or as first line management for patients with PHT and NYHA functional class II and III.<sup>158,159</sup> (High quality of evidence, strong recommendation). It is recommended that its use should be considered for patients of functional class IV.<sup>158–161</sup> (Low quality of evidence, weak recommendation).
- For patients with pulmonary hypertension NYHA functional class III and IV, doses of 20 mg/day are recommended, gradually increased to 40 mg/day as tolerated by the patient, as second line therapy and in combination with immunosuppressant therapy.<sup>149,153,158,159</sup> (Moderate quality of evidence, weak recommendation). Vardenafil is not recommended due to a lack of evidence for the treatment of pulmonary hypertension.<sup>159</sup> (Moderate quality of evidence, weak recommendation)
- Combined therapy: combined therapy with vasodilators, PDE-5 inhibitors and endothelin-1 receptor antagonists is not recommended for patients with SLE due to a lack of evidence.<sup>153,154</sup> (Moderate quality of evidence, weak recommendation)

<sup>a</sup> The PPI sildenafil is not indicated in Mexico for pulmonary hypertension, and is only available in presentations of 50 and 100 mg. The dosage can be adjusted or start with doses of 25 mg, lower than the 50 and 100 mg tablet fractions.

in the working group who are the signatories of this CPG. [Table 4](#) presents the recommendations for managing the general manifestations of SLE, and [Tables 5–10](#) present the recommendations for the treatment of the renal, cardiovascular, pulmonary, neurological, haematological, and gastrointestinal manifestations of the disease.

**Research Needs**

SLE, because it is a rare disease, is a less frequent subject of research than other diseases. Therefore, there is a significant need for evidence on effective treatments that also have a lower

rate of adverse events. The working panel identified a series of knowledge gaps, and made recommendations so that clinicians, researchers and the pharmaceutical industry can focus their efforts on these research needs to provide increasingly better treatments for patients with this disease.

- 1) In general, the following need to be designed:
  - a) National multicentre prospective cohort studies.
  - b) Comparative studies with populations from other countries.
  - c) Controlled clinical trials on treatment of the neuropsychiatric manifestations of lupus.

**Table 7**  
Recommendations for Pulmonary Manifestations.

<p><i>Pleuritis with or without pleural effusion</i></p> <ul style="list-style-type: none"> <li>– NSAIDs: these are recommended as a treatment group, preferably naproxen at doses of 250–500 mg every 12 h for 1–2 weeks, although any NSAID is acceptable. It is recommended that contraindications (gastrointestinal, renal failure, uncontrolled systemic arterial hypertension, heart failure) for NSAIDs should be assessed.<sup>162,163</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Glucocorticoids: these are indicated after there has been no therapeutic response with NSAIDs over a period of 1–2 weeks. We recommend the use of prednisone in doses of 20 mg/day, tapered over a period of 2–3 weeks.<sup>162,163</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Other immunosuppressants: These are not recommended due to a lack of evidence, and because they are rarely required in this context. (Good practice recommendation)</li> </ul> <p><i>Acute lupus pneumonitis</i></p> <ul style="list-style-type: none"> <li>– Glucocorticoids: prednisone is recommended at doses of 1 mg/kg/day for 3 days, and assessing the clinical response; if there is no response, then consider methylprednisolone pulses at doses of 1 g/day for 3 days.<sup>164</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Cyclophosphamide: in cases refractory to GC, CYC can be considered in monthly pulses (from .5 to 1 g/m<sup>2</sup> of body surface; from 3 to 6 monthly pulses) monitoring for toxic effects (haemorrhagic cystitis, myelotoxicity, infections). Premedicate with hydration, antiemetic and MESNA.<sup>164</sup> (Low quality of evidence, weak recommendation)</li> <li>– Intravenous immunoglobulin: it is recommended for consideration in refractory cases or where treatment with immunosuppressants is contraindicated, at a dose of 2 g/kg for 5 days (400 mg/kg/day).<sup>163–165</sup> (Low quality of evidence, weak recommendation)</li> </ul> <p><i>Interstitial lung disease in systemic lupus erythematosus</i></p> <ul style="list-style-type: none"> <li>– General measures: Smoking must be given up, consider supplementary oxygen as necessary, and influenza and pneumococcal vaccination.<sup>65</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Glucocorticoids: prednisone is recommended at doses of .5–1 mg/kg/day, monitor respiratory symptoms, and carbon monoxide diffusion capacity to define response, and monitor for adverse effects (infections, osteoporosis, systemic arterial hypertension, secondary diabetes mellitus).<sup>166</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Immunosuppressants: monthly pulses of CYC, azathioprine, MMF are recommended as steroid savers.<sup>167</sup> Azathioprine and MMF are used at the usual doses in mild to moderate cases. Monthly CYC pulses of .5–1 g/m<sup>2</sup> of body surface area (from 6 to 12 months) is reserved for severe cases.<sup>165,166</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Rituximab: rituximab is recommended for use in refractory cases at the usual doses of 375 mg/m<sup>2</sup> of body surface area in 4 weekly doses or 1 g total dose for administration in 2 separate doses, separated by 15 days.<sup>165,166</sup> (Low quality of evidence, weak recommendation)</li> </ul> <p><i>Pulmonary haemorrhage in systemic lupus erythematosus</i><sup>165</sup></p> <ul style="list-style-type: none"> <li>– Glucocorticoids: the use of methylprednisolone pulses at doses of 1 g/day for 3–5 days is recommended.<sup>168,169</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Immunosuppressants: the use of CYC pulses is recommended at doses of .5–1 g/m<sup>2</sup> of body surface area (from 6 to 12 monthly pulses).<sup>169,170</sup> (Low quality of evidence, strong recommendation). Use of MMF (from 2 to 3 g/day) is recommended, and azathioprine (from 2 to 3 mg/kg/day).<sup>168,170</sup> (Low quality of evidence, strong recommendation). Rituximab is recommended with or without pulses of CYC for refractory cases or cases intolerant to CYC pulses.<sup>171</sup> (Low quality of evidence, strong recommendation)</li> <li>– Intravenous immunoglobulin: recommended for cases that are refractory to the usual treatment at doses of 2 g/kg by infusion for 5 days (400 mg/kg/day).<sup>170</sup> (Low quality of evidence, strong recommendation)</li> <li>– Factor VIIa activated recombinant: consider the use of factor VIIa recombinant for refractory cases.<sup>172</sup> (Low quality of evidence, weak recommendation)</li> <li>– Antibiotics: in the event of pulmonary haemorrhage associated with pulmonary infectious processes, bronchial secretion cultures are recommended, and antibiotic coverage where necessary.<sup>170</sup> (Moderate quality of evidence, strong recommendation)</li> </ul>
---

**Table 8**  
Recommendations for Neurological Manifestations.

<p><i>General recommendations</i><sup>165</sup></p> <ul style="list-style-type: none"> <li>– Patients with SLE and a neurological or psychiatric manifestation must be studied in the same way as patients without lupus.<sup>26</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– According to the neurological or psychiatric manifestation presented by the patient, electroencephalogram, nerve conduction velocities, electromyography, lumbar puncture, neuropsychological tests, somatosensory evoked potentials, and brain and spinal magnetic resonance imaging including conventional T1, T2 and FLAIR sequences, as well as T1 gadolinium-enhanced sequence should be performed.<sup>173</sup> (Moderate quality of evidence, strong recommendation)</li> </ul> <p><i>Cognitive dysfunction</i><sup>165</sup></p> <ul style="list-style-type: none"> <li>– Management of associated factors such as anxiety and depression is recommended, and control of cardiovascular risk factors as well as psychological support, since this can prevent major cognitive impairment.<sup>174</sup> (Low quality of evidence, weak recommendation)</li> </ul> <p><i>Seizures</i><sup>165</sup></p> <ul style="list-style-type: none"> <li>– Antiepileptic drugs: antiepileptic drugs are recommended if there are recurrent seizures or if there have been at least 2 episodes in the first 24 h or there is epileptogenic activity on the electroencephalogram.<sup>175</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Methylprednisolone: For refractory seizures associated with SLE activity, intravenous methylprednisolone is recommended (1 g/day for 3 days), followed by prednisone (1 mg/kg/day for no more than 3 months), and tapered according to the activity of the disease.<sup>176</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Cyclophosphamide: Concomitant intravenous CYC .75 g/m<sup>2</sup> of body surface area every month for 12 months is recommended.<sup>176</sup> (Moderate quality of evidence, strong recommendation)</li> </ul> <p><i>Peripheral neuropathy, myelopathy and optic neuritis</i><sup>165</sup></p> <ul style="list-style-type: none"> <li>– Methylprednisolone: Intravenous methylprednisolone is recommended at 1 g/day for 3 days, followed by prednisone (1 mg/kg/day for no more than 3 months), tapered according to the activity of the disease.<sup>176–179</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Cyclophosphamide: Concomitant intravenous CYC, .75 g/m<sup>2</sup> of body surface area every month for 12 months is recommended.<sup>176–178</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Immunoglobulin: intravenous immunoglobulin can be used at a dose of 2 g/kg, divided over 5 days.<sup>177,178,180–182</sup> (Moderate quality of evidence, weak recommendation)</li> </ul>
--

Table 8 (Continued)

<p><b>Movement disorders (chorea)</b><sup>165</sup></p> <ul style="list-style-type: none"> <li>– Antiplatelet drugs: aspirin is recommended in chorea associated with antiphospholipid antibodies and anticoagulation associated with antiphospholipid antibody syndrome.<sup>183–186</sup> (Low quality of evidence, weak recommendation)</li> <li>– Dopamine antagonists: symptomatic therapy with dopamine antagonists is recommended.<sup>175</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Other: there are case reports that recommend that methylprednisolone, CYC, azathioprine and rituximab could be a therapeutic option for refractory patients.<sup>183,187</sup> (Low quality of evidence, weak recommendation)</li> </ul> <p><b>Psychosis</b><sup>165</sup></p> <ul style="list-style-type: none"> <li>– Prednisone: Prednisone at 1 mg/kg/day for 8 weeks is recommended, with gradual tapering to 5 mg a day.<sup>188</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Cyclophosphamide: concomitant use of intravenous CYC is recommended at a dose of .75 g/m<sup>2</sup> of body surface area every month for 6 months.<sup>188,189</sup> (Moderate quality of evidence, strong recommendation)</li> </ul>
---

**Table 9**

Recommendations for Haematological Manifestations.

<p><b>Thrombocytopenia</b></p> <ul style="list-style-type: none"> <li>– Glucocorticoids: in cases of thrombocytopenia, 1 mg/kg/day of prednisone (or equivalent) is recommended until platelet counts above 100,000 cell/mcl are achieved, with no signs of bleeding, tapering the dose of GC until discontinuing it, and adding another immunosuppressant to reduce the risk of relapse.<sup>190–192</sup> (Moderate quality of evidence, strong recommendation). In cases of severe thrombocytopenia (fewer than <math>15 \times 10^9</math>/cell/mcl) or with signs of life-threatening bleeding, methylprednisolone pulses are recommended (1 g/24 h, intravenous, for 3–5 days, according to the gravity of symptoms) to obtain more rapid responses, ensuring continuation at between .5 and 1 mg/kg/day of prednisone or its equivalent to prevent the risk of relapse. It is recommended that these doses should be continued until counts above 50,000 cell/mcl are achieved, and further immunosuppressant should be considered.<sup>190–192</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Intravenous immunoglobulin: is recommended as rescue therapy only for patients with a poor response to GC (i.e., who have received pulses of methylprednisolone for 3–5 days or prednisone or its equivalent, at 1 mg/kg/day for more than 4 weeks, and platelet counts do not exceed 50,000 cel/mcl or there are signs of active life-threatening bleeding). It is recommended at a dose of 1 g/kg of weight on day 1 and day 2. Response is usually transient (10 days on average).<sup>193–196</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Danazol: is recommended as combined therapy with oral GC, at a dose of 200–800 mg/day according to the severity of the thrombocytopenia.<sup>197,198</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Antimalarials: are used as adjunct therapy with oral GC at doses between 200 and 400 mg/day, according to the severity of the thrombocytopenia.<sup>199</sup> (Low quality of evidence, weak recommendation)</li> <li>– Biologics (rituximab): recommended principally in the event of failure with other immunosuppressants. The regimen of 375 mg/m<sup>2</sup> of body surface area is recommended every week for 4 weeks or the regimen of 1 g intravenously on day zero and day 15. The best response is observed when combined with oral GC 1 mg/kg/day of prednisone or its equivalent and with tapering doses over 3 months or less.<sup>200,201</sup> (High quality of evidence, strong recommendation). The low dose regimen is also recommended for consideration, which comprises 100 mg intravenously on days 0, 7, 14 and 21 (i.e., 4 doses, one per week).<sup>200,201</sup> (Moderate quality of evidence, weak recommendation)</li> <li>– Splenectomy: principally recommended if thrombocytopenia has been refractory to various immunosuppressant treatments (i.e., final line treatment).<sup>202–205</sup> (Low quality of evidence, weak recommendation)</li> <li>– Cyclophosphamide: recommended principally for use in patients who have not responded to the previous treatment; it can even be used as rescue therapy after splenectomy. Intravenous doses of 500 mg to 1.2 g/month for 3–6 months are recommended, according to the severity of the thrombocytopenia, and clinical response. In very GC-dependent patients, it can be considered as a saving agent for this group of drugs.<sup>206–208</sup> (Low quality of evidence, weak recommendation)</li> <li>– Mycophenolate mofetil: recommended for patients who are refractory to the other lines of treatment. The usual dose is between 1 and 2.5 g/day, according to tolerance and clinical response.<sup>38,209</sup> (Low quality of evidence, weak recommendation)</li> <li>– Azathioprine recommended for use in patients refractory to the other lines of treatment. The recommended dose ranges from .5 to 2 mg/kg/day, according to tolerance and response.<sup>190,210,211</sup> (Low quality of evidence, weak recommendation)</li> <li>– Eltrombopag: not recommended for routine use due to a lack of evidence.<sup>212,213</sup> (Low quality of evidence, strong recommendation)</li> </ul> <p>Platelet transfusion: recommended for patients with platelet counts below 10,000 cell/mcl irrespective of whether there are signs of bleeding or counts below 50,000 cell/mcl with active bleeding. In counts above 50,000 cell/mcl, it is only recommended if there is active life or function-threatening bleeding. Ideally, all patients who are to undergo a minor invasive procedure (for example, central line placement, thoracocentesis, etc) require at least 50,000 cell/mcl. With procedures such as surgical interventions or higher risk procedures (kidney biopsy, for example), preferably counts above 100,000 cell/mcl should be maintained.<sup>214</sup> (Moderate quality of evidence, strong recommendation)</p> <p><b>Autoimmune haemolytic anaemia</b></p> <ul style="list-style-type: none"> <li>– Biologics (rituximab): principally recommended for use when treatment with other immunosuppressants has failed. The regimen of 375 mg/m<sup>2</sup> of body surface area (intravenous) can be used every week for 4 weeks or a regimen of 1 g intravenously on day zero and day 15.<sup>215,216</sup> (Good quality of evidence, strong recommendation). The low-dose regimen comprising 100 mg intravenously on days 0, 7, 14 and 21 (4 doses, one per week) can be considered. The best response to this regimen is observed when combined with oral GC 1 mg/kg/day of prednisone or equivalent, with tapering doses over 3 months or less.<sup>215–219</sup> (Low quality of evidence, weak recommendation)</li> <li>– Glucocorticoids: to attempt to obtain rapid responses (in approx 48–72 h) in situations where the anaemia is life-threatening, pulses of intravenous methylprednisolone are recommended (1 g/day, for 3–5 days, according to the severity of the anaemia). It is recommended that when going on to oral GC (1 mg/kg/day of prednisone or equivalent), this dose should be maintained for 4 weeks at least, and subsequent tapering should be slow and gradual to prevent relapses, until there is a different immunosuppressant and the haemoglobin count is stable and above 7 g/dl.<sup>43,220–223</sup> (Good quality of evidence, strong recommendation)</li> <li>– Azathioprine: recommended for use as a GC saving agent in cases where there has been relapse on discontinuation or tapering, at doses of .5–2 mg/kg day, according to tolerance and clinical response.<sup>211,224</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Danazol: recommended for refractory patients at doses of 200–800 mg/day, but as a coadjuvant with other immunosuppressants.<sup>197,225–227</sup> (Moderate quality of evidence, strong recommendation)</li> </ul> <p>Intravenous immunoglobulin: not recommended due to a lack of sufficient evidence for its recommendation.<sup>228</sup> (Low quality of evidence, weak recommendation)</p> <ul style="list-style-type: none"> <li>– Mycophenolate mofetil: recommended for use in patients refractory to the other treatment lines. Doses of 1–2.5 g/day, according to tolerance and clinical response. It can also operate as a GC saver.<sup>229–231</sup> (Low quality of evidence, weak recommendation)</li> <li>– Cyclophosphamide: recommended principally for use in patients who have not responded to first or second line treatments; doses of between 500 and 1.2 g/month (intravenous) for 3–6 months, according to the severity of the anaemia and clinical response.<sup>43,232</sup> (Low quality of evidence, weak recommendation)</li> <li>– Splenectomy: not recommended while there is no available information on their efficacy and safety as routine treatment, except in refractory patients where it is considered that the possible benefit outweighs the risks.<sup>43,233</sup> (Low quality of evidence, weak recommendation)</li> <li>– Blood transfusion: not recommended except in life-threatening situations or conditions such as low cardiac output, ischaemic heart disease, severe neurological disorders, etc., always combined with the supervision of haematological doctors before using packs of red cells.<sup>234</sup> (Moderate quality of evidence, strong recommendation)</li> </ul>
---

Table 9 (Continued)

<p><b>Neutropenia</b></p> <ul style="list-style-type: none"> <li>– Infection vs manifestation of the disease: infection and the toxic effect of drugs, respectively, must be discounted first, before attributing the manifestation to activity of the disease. (Good practice recommendation)</li> <li>– Granulocyte-colony stimulating factor: in neutropenia &lt;1000/<math>\mu</math>l, associated with fever or infection starting with 300 <math>\mu</math>g/day is recommended, and continuing with the minimum effective dose to achieve a neutrophil count above 1000/<math>\mu</math>l.<sup>235–240</sup> (Low quality of evidence, strong recommendation)</li> <li>– Glucocorticoids: doses of between .5 and 1 mg/kg/day are recommended of prednisone or its equivalent.<sup>235,236,241</sup> (quality of evidence, weak recommendation)</li> <li>– Azathioprine: doses of up to 2.5 mg/kg/day are recommended, according to response and tolerance.<sup>241</sup> (Very low quality of evidence, weak recommendation)</li> <li>– Mycophenolate mofetil: not recommended for use due to the lack of evidence on the optimal dose.<sup>235,241</sup> (Very low quality of evidence, weak recommendation)</li> <li>– Cyclosporine: not recommended due to the lack of evidence on the optimal dose.<sup>235,241</sup> (Very low quality of evidence, weak recommendation)</li> <li>– Rituximab: recommended in disease refractory to doses of 375 mg/m<sup>2</sup> of body surface area weekly for 4 weeks or doses of 1 g day zero, and day 14.<sup>235,241</sup> (Very low quality of evidence, weak recommendation)</li> </ul> <p><b>Thrombotic thrombocytopenic purpura</b></p> <ul style="list-style-type: none"> <li>– Plasmapheresis: it is recommended that plasmapheresis should be started as soon as a diagnosis is suspected (in the first 4–8 h). Replacement should be with fresh frozen plasma.<sup>242–245</sup> (Low quality of evidence, strong recommendation)</li> <li>– Glucocorticoids: recommended for use in combination with plasmapheresis. Pulse methylprednisolone (1 g daily for 5 days) or prednisone (or equivalent) at doses of 1 mg/kg/day.<sup>242–245</sup> (Low quality of evidence, strong recommendation)</li> <li>– Cyclophosphamide: is recommended, even though there is no consensus as to the dose.<sup>242–244</sup> (Very low quality of evidence, weak recommendation)</li> <li>– Mycophenolate mofetil: recommended if CYC is contraindicated or has reached its maximum effect; there is no consensus as to the dose.<sup>244</sup> (Very low quality of evidence, weak recommendation)</li> <li>– Rituximab: recommended for refractory cases, increasing the response percentage. The recommended dose is 375 mg/m<sup>2</sup> of body surface area weekly for 4 weeks. It is recommended that plasmapheresis should be delayed for at least 4 h after rituximab infusion.<sup>242,244,245</sup> (Very low quality of evidence, weak recommendation)</li> <li>– Vincristine: could be used for refractory cases (as an option after rituximab) at single doses of 1.4 mg/m<sup>2</sup> of body surface, with a maximum of 2 mg as the total dose.<sup>242,243,245,246</sup> (Very low quality of evidence, weak recommendation).</li> </ul> <p><b>Haemophagocytic syndrome</b></p> <ul style="list-style-type: none"> <li>– General measures: provide support treatment (fluid resuscitation, antibiotics, cover transfusion requirements). Look for and treat foci of infection. (Good practice)</li> <li>– Glucocorticoids: pulse methylprednisolone or prednisone (or equivalent) is recommended, there is no consensus as to dose.<sup>245,247</sup> (Low quality of evidence, strong recommendation)</li> <li>– Cyclophosphamide: pulses of 500 mg to 1 g monthly for 6 months<sup>247</sup> are recommended. (Low quality of evidence, weak recommendation)</li> <li>– Cyclosporine: doses of 2–5 mg/kg/day<sup>247</sup> are recommended. (Low quality of evidence, weak recommendation)</li> <li>– Intravenous immunoglobulin: not recommended.<sup>247</sup> (Low quality of evidence, strong recommendation)</li> </ul>
---

**Table 10**

Recommendations for Gastrointestinal Manifestations.

<p><b>Intestinal pseudo-obstruction</b></p> <ul style="list-style-type: none"> <li>– Glucocorticoids: the use of GC at high doses should be considered (intravenous methylprednisolone 1 g every 24 h for 3–5 days followed by the equivalent of prednisone 1 mg/kg/day) for patients with intestinal pseudo-obstruction.<sup>248,249</sup> (Low quality of evidence, strong recommendation)</li> <li>– Immunosuppressants: the concomitant use of GC with immunosuppressants such as CYC, cyclosporine A, methotrexate, azathioprine or tacrolimus<sup>249,250</sup> should be considered. (Low quality of evidence, strong recommendation)</li> <li>– Intravenous immunoglobulin: should be considered for use in patients who are refractory to massive doses of GC.<sup>249,250</sup> (Low quality of evidence, strong recommendation)</li> </ul> <p><b>Autoimmune pancreatitis</b></p> <ul style="list-style-type: none"> <li>– Glucocorticoids: GC should be considered for use at high doses (equivalent to prednisone 1 mg/kg/day) in patients with acute pancreatitis. For patients who do not respond to the initial dose of prednisone at 1 mg per kg of weight, pulse methylprednisolone 1 g i.v. could be used every 24 h in 3 doses.<sup>251,252</sup> (Low quality of evidence, strong recommendation).</li> <li>– Immunosuppressants: concomitant use of GC and immunosuppressants such as CYC, methotrexate or azathioprine is recommended for consideration.<sup>251,252</sup> (Low quality of evidence, weak recommendation)</li> <li>– Plasmapheresis: the use of plasmapheresis should be considered for patients refractory to GC therapy.<sup>253</sup> (Moderate quality of evidence, strong recommendation)</li> </ul> <p><b>Protein losing enteropathy</b></p> <ul style="list-style-type: none"> <li>– Glucocorticoids: high doses of GC are recommended (equivalent of prednisone 1 mg/kg/day) for patients with protein losing enteropathy. Methylprednisolone pulses should be considered if the patient has other severe complications of the disease, such as hypoalbuminaemia causing capillary leakage, and secondarily severe pleural or pericardial effusion or severe liver involvement.<sup>254–256</sup> (Moderate quality of evidence, strong recommendation)</li> <li>– Immunosuppressants: concomitant use of GC and immunosuppressants such as CYC, cyclosporine A, methotrexate, azathioprine or MMF<sup>254–256</sup> should be considered. (Low quality of evidence, strong recommendation)</li> </ul> <p><b>Intestinal vasculitis</b></p> <ul style="list-style-type: none"> <li>– Glucocorticoids: GC at high doses should be considered (methylprednisolone: 1 g intravenously every 24 h for 3–5 days followed by the equivalent of prednisone 1 mg/kg/day) for patients with intestinal vasculitis.<sup>257–259</sup> (Low quality of evidence, strong recommendation)</li> <li>– Immunosuppressants: concomitant use of GC and intravenous CYC should be considered for patients with intestinal vasculitis associated with other severe manifestations of the disease (SLE) or patients with recurring vasculitis.<sup>258</sup> (Low quality of evidence, strong recommendation)</li> <li>– Surgery: consider abdominal laparotomy if there is no improvement in pain in the first 24–48 h from initiating GC pulse therapy. (Good practice)</li> </ul>
---

2) There is a need for clinical trials for the treatment of the articular manifestations of SLE.

3) More evidence is required on the efficacy and safety of tacrolimus in severe SLE, calcium antagonists and immunosuppressant medication (MMF and CYC) in patients with pulmonary hypertension, of CYC, azathioprine, mycophenolate mofetil, danazol, antimalarials in the treatment of patients with SLE and thrombocytopenia or haemolytic anaemia, of CYC for haemophagocytic syndrome and thrombotic thrombocytopenic purpura, giving multiple vaccinations

at one visit and tetanus vaccination, recombinant human papilloma virus quadrivalent vaccine, hepatitis B virus and zoster herpes in patients with moderate and severe disease activity.

4) Therapeutic evidence of the use of splenectomy will require more evidence from retrospective studies, since it is not very feasible to undertake a controlled clinical trial.

5) Studies are required on the optimal duration of treatment, and dose tapering schemes when remission of symptoms has been achieved.

- 6) Studies with greater statistical power are required on gastrointestinal involvement in lupus, since the current studies are case series.
- 7) Studies are required to determine the required dose of CYC for haemophagocytic syndrome, and thrombotic thrombocytopenic purpura.

### Conflict of Interests

Daniel Xibille-Friedman has received honoraria from GlaxoSmithKline for training activities and in clinical trials. Sandra Carrillo-Vázquez has received honoraria from Abbvie, Bristol Myers Squibb, Eli Lilly, Novartis, Pfizer, Roche, Takeda and Janssen. Lilia Andrade-Ortega has received honoraria from Bristol Myers Squibb, Novartis, Pfizer, Roche, Janssen. Miguel Ángel Saavedra has received honoraria from UCB and Pfizer. Leonardo Limón-Camacho has received honoraria from Bristol Myers Squibb, UCB, Pfizer, Janssen, Roche, Lilly and Amgen. Leonor Barile Fabris has received honoraria from Abbvie, Jansen, Roche, Bristol Myers Squibb, UCB, Novartis, Pfizer and GlaxoSmithKline.

Marcela Pérez-Rodríguez, Everardo Álvarez-Hernández, Francisco Javier Aceves, Mario C. Ocampo-Torres, Conrado García-García, José Luis García-Figueroa, Javier Merayo-Chalico, Ana Barrera-Vargas, Margarita Portela-Hernández, Sandra Sic-sik, Víctor Manuel Rosales-Don Pablo, Aline Martínez, Pilar Prieto-Seyffert, Mario Pérez-Cristóbal, Zuluy Castro-Colín, Azucena Ramos, Gabriela Huerta-Sil, María Fernanda Hernández-Cabrera, Luis Javier Jara and Lizbet Tinajero-Nieto have no conflict of interests to declare.

### Acknowledgements

We would like to thank M. en C. Guadalupe Olvera Soto for her invaluable support in the search of the articles used in the literature review; we would also like to thank GlaxoSmithKline for their unconditional educational support.

### References

1. Somers E, Marder W, Cagnoli P, Lewis E, DeGuire P, Gordon E, et al. Population-based incidence and prevalence of systemic lupus erythematosus. The Michigan Lupus Epidemiology and Surveillance Program. *Arthritis Rheumatol.* 2014;66:369–78.
2. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. *Lupus.* 2006;15:308–18.
3. Pons-Estel GJ, Catoggio LJ, Cardiel MH, Bonfa E, Caeiro F, Sato E, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. *Lupus.* 2015;24:536–45.
4. Diagnóstico y tratamiento de lupus eritematoso mucocutáneo. CENETEC. Available from: <http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/533.GPC.Lupusmucocutxneo/GER.LupusEritematoso.pdf> [accessed 7.12.2017].
5. Saavedra-Salinas MA, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-Salinas CA, Álvarez Nemegeyi J, et al. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. *Reumatol Clin.* 2015;11:295–304.
6. Práctica clínica sobre lupus eritematoso sistémico. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud; 2015. Available from: [http://www.guiasalud.es/GPC/GPC\\_549.Lupus.SESCS.compl.pdf](http://www.guiasalud.es/GPC/GPC_549.Lupus.SESCS.compl.pdf) [accessed 7.12.2017].
7. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res.* 2012;64:797–808.
8. Burgos PI, McGwin G Jr, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). *Ann Rheum Dis.* 2011;70:393–4.
9. Pons Estel B, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The Gladel Multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus. Ethnic and disease heterogeneity among "Hispanics". *Medicine.* 2004;83:1–17.
10. Barile L, Lavalle C. Transverse myelitis in SLE. The effect of IV cyclophosphamide and methylprednisolone. *J Rheumatol.* 1992;19:370.
11. Barile L, Pons-Estel B, on behalf of GLADEL (Grupo Latinoamericano para el Estudio del Lupus). Clinical characteristics of neuropsychiatric involvement in an inception cohort of 1214 Latin-American patients with SLE. *Lupus.* 2001;10 Suppl:S51.
12. Perez-Guerrero EE, Gamez-Nava JI, Muñoz-Valle JF, Cardona-Muñoz EG, Bonilla-Lara D, Fajardo-Robledo NS, et al. Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus. *Clin Exp Med.* 2018;18:109–17.
13. Mejía-Vilet JM, Arreola-Guerra JM, Córdova-Sánchez BM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R. Comparison of lupus nephritis induction treatments in a Hispanic population: a single-center cohort analysis. *J Rheumatol.* 2015;42:2082–91.
14. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. *Lupus.* 2010;19:213–9.
15. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. *West J Med.* 1999;170:348–51.
16. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol.* 2011;64:383–94.
17. Woolf S, Schünemann HJ, Eccles MP, Grimshaw JM, Shekelle P. Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations. *Implement Sci.* 2012;7:61.
18. Shukla V, Bai A, Milne S, Wells G. Systematic review of the evidence grading system for grading level of evidence. *German J Evidence Qual Health Care.* 2008;102:43.
19. Guyatt G, Vist G, Falck-Ytter Y, Kunz R, Magrini N, Schunemann H. An emerging consensus on grading recommendations? *ACP J Club.* 2006;144:A8–9.
20. Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. *J Clin Epidemiol.* 2015;68:597–600.
21. Van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis.* 2017;76:554–61.
22. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Catoggio LJ, Drenkard C, Sarano J, et al. Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). *Ann Rheum Dis.* 2017;76:2071–4.
23. Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). *Ann Rheum Dis.* 2016;75:1615–21.
24. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. *Arthritis Rheum.* 2004;50:3418–26.
25. Calvo-Alén J, Silva-Fernández L, Úcar-Angulo E, Pego-Reigosa JM, Olivé A, Martínez-Fernández C, et al. Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. *Reumatol Clin.* 2013;9:281–96.
26. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus (SLE), report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCIIT). *Ann Rheum Dis.* 2008;67:195–205.
27. Miranda-Hernández D, Cruz-Reyes C, Monsebaiz-Mora C, Gómez-Bañuelos E, Ángeles U, Jara LJ, et al. Active haematological manifestations of systemic lupus erythematosus lupus are associated with a high rate of in-hospital mortality. *Lupus.* 2017;26:640–5.
28. Fernando MM, Isenberg DA. How to monitor SLE in routine clinical practice. *Ann Rheum Dis.* 2005;64:524–7.
29. Hoes JN, Jacobs JWG, Boers M, Boumpas D, Buttgerit F, Caeyers N, et al. EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis.* 2007;66:1560–7.
30. Hu C, Lu L, Wan JP, Wen C. The pharmacological mechanisms and therapeutic activities of hydroxychloroquine in rheumatic and related diseases. *Curr Med Chem.* 2017;24:2241–9.
31. Molad Y, Gorshtein A, Wysesbeek AJ, Guedj D, Majadla R, Weinberger A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. *Lupus.* 2002;11:356–61.
32. Fessler BJ, Alarcón GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. *Arthritis Rheum.* 2005;52:1473–80.
33. Pons-Estel GJ, Alarcón GS, Hachuel L, Boggio G, Wojdyla D, Pascual-Ramos V, et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. *Rheumatology (Oxford).* 2012;51:1293–8.
34. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. *Nat Rev Rheumatol.* 2012;8:522–33.

35. Jiménez-Palop M. Antipalúdicos: actualización de su uso en enfermedades reumáticas. *Reumatol Clin.* 2006;2:190–201.
36. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. *N Engl J Med.* 1991;324:150–4.
37. Bori Segura G, Hernández Cruz B, Gobbo M, Lanás Arbeloa A, Salazar Páramo M, Terán Estrada L, et al. Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology. *Reumatol Clin.* 2009;5:3–12.
38. Dall'Era M, Chakravarty EF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. *Curr Rheumatol Rep.* 2011;13:308–16.
39. Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of cutaneous lupus erythematosus. *J Clin Aesthet Dermatol.* 2010;6:27–38.
40. Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of lupus nephritis. *Cochrane Database Syst Rev.* 2012;12:CD002922.
41. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. *Ann Rheum Dis.* 2010;69:2083–9.
42. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. *N Engl J Med.* 2011;365:1886–95.
43. Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. *Lupus.* 2006;15:223–31.
44. Dall'Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. *Curr Opin Rheumatol.* 2011;23:454–8.
45. Buttgerief F, da Silva JA, Boers M, Burmester G-R, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answer in rheumatology. *Ann Rheum Dis.* 2002;61:718–22.
46. Mosca M, Tani C, Carli L, Bombardieri S. Glucocorticoids in systemic lupus erythematosus. *Clin Exp Rheumatol.* 2011;29:S126–9.
47. Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. *Ann Rheum Dis.* 2010;69:1144–7.
48. Yuen HK, Cunningham MA. Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review. *Ther Clin Risk Manag.* 2014;10:775–86.
49. Arriens C, Hynan LS, Lerman RH, Karp DR, Mohan C. Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in systemic lupus erythematosus. *Nutr J.* 2015;14:82.
50. Lima GL, Paupitz J, Aikawa NE, Takayama L, Bonfá E, Pereira RM. Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial. *Arthritis Care Res (Hoboken).* 2016;68:91–8.
51. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2010;62:3077–87.
52. Petri MA, Martin RS, Scheinberg MA, Furie RA. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the phase 2 clinical trial with belisbimod. *Lupus.* 2017;26:27–37.
53. Schwarting A, Schroeder JO, Alexander T, Schmalzing M, Fiehn C, Specker C, et al. First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSERVE Germany Study. *Rheumatol Ther.* 2016;3:271–90.
54. Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. *Ann Rheum Dis.* 2014;73:838–44.
55. Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW, et al. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. *Lupus Sci Med.* 2014;1:e000031.
56. Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE). Results from a nationwide cohort in Germany (GRAID). *Lupus.* 2013;22:1142–9.
57. Greco CM, Kao AH, Maksimowicz-McKinnon K, Glick RM, Houze M, Sereika SM, et al. Acupuncture for systemic lupus erythematosus: a pilot RCT feasibility and safety study. *Lupus.* 2008;17:1108–16.
58. Bogdanovic G, Stojanovich L, Djokovic A, Stanisavljevic N. Physical activity program is helpful for improving quality of life in patients with systemic lupus erythematosus. *Tohoku J Exp Med.* 2015;237:193–9.
59. Zhou WJ, Yang CD. The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. *Lupus.* 2009;18:807–12.
60. Rovin BH, Tang Y, Sun J, Nagaraja HN, Hackshaw KV, Gray L, et al. Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy. *Kidney Int.* 2005;68:747–59.
61. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. *J Am Soc Nephrol.* 2004;15:241–50.
62. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. *Kidney Int.* 2007;71:491–5.
63. Pagni F, Galimberti S, Goffredo P, Basciu M, Malachina S, Pilla D, et al. The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. *Nephrol Dial Transplant.* 2013;28:3014–23.
64. Subils G, Alba P, Gobbi C, Astesana P, Babini A, Albiero E. The repeated biopsy in patients with lupus nephritis. *Rev Fac Cien Med Univ Nac Cordoba.* 2014;71:165–70.
65. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. *Arch Intern Med.* 1998;158:1769–76.
66. Louie JS, Nies KM, Shoji KT, Fraback RC, Abrass C, Border W, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. *Ann Intern Med.* 1978;88:790–2.
67. Lu CC, Wang YC, Lai JH, Lee TS, Lin HT, Chang DM. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. *Vaccine.* 2011;29:444–50.
68. Borba EF, Saad CG, Pasoto SG, Calich AL, Aikawa NE, Ribeiro AC, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? *Rheumatology (Oxford).* 2012;51:1061–9.
69. Wiesik-Szewczyk E, Romanowska M, Mielnik P, Chwalińska-Sadowska H, Brydak LB, Olesińska M, et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. *Clin Rheumatol.* 2010;29:605–13.
70. Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. *Vaccine.* 2006;24:3217–23.
71. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. *Ann Rheum Dis.* 2006;65:913–8.
72. Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. *Rheumatology (Oxford).* 2009;48:1294–9.
73. Wallin L, Quintilio W, Locatelli F, Cassel A, Silva MB, Skare TL. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. *Acta Reumatol Port.* 2009;34:498–502.
74. Ristow SC, Douglas RG Jr, Condemni JJ. Influenza vaccination of patients with systemic lupus erythematosus. *Ann Intern Med.* 1978;88:786–9.
75. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. Influenza immunization in systemic lupus erythematosus. A double-blind trial. *Ann Intern Med.* 1978;88:729–34.
76. Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huang DB, et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. *Arthritis Rheum.* 2011;63:3502–11.
77. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, et al. Antigen-specific antibody responses in lupus patients following immunization. *Arthritis Rheum.* 1998;41:1828–34.
78. Mercado U, Acosta H, Avendaño L. Influenza vaccination of patients with systemic lupus erythematosus. *Rev Invest Clin.* 2004;56:16–20.
79. Urowitz MB, Anton A, Ibanez D, Gladman DD. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. *Arthritis Care Res (Hoboken).* 2011;63:1517–20.
80. Jarrett MP, Schiffman G, Barland P, Grayzel AI. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. *Arthritis Rheum.* 1980;23:1287–93.
81. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. *Clin Infect Dis.* 2002;34:147–53.
82. Pisoni C, Sarano J, Benchetrit G, Rodríguez D, Suárez L, Perrota C, et al. Antipneumococcal vaccination in patient with systemic lupus erythematosus. *Medicina (B Aires).* 2003;63:388–92.
83. Tarján P, Sipka S, Maródi L, Nemes E, Lakos G, Gyimesi E, et al. No short-term immunological effects of Pneumococcal vaccination in patients with systemic lupus erythematosus. *Scand J Rheumatol.* 2002;31:211–5.
84. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. *Ann Rheum Dis.* 2013;72:659–64.
85. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. *JAMA.* 2009;302:750–7.
86. Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfá E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. *Lupus.* 2007;16:350–4.
87. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. *J Rheumatol.* 2000;27:377–9.
88. Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. *J Rheumatol.* 2013;40:1875–80.

89. Ortiz García A. Management of problematic clinical situations in rheumatoid arthritis patients. *Reumatol Clin.* 2009;5:61–5.
90. Merayo-Chalico J, Gonzalez Contreras M, Ortiz-Hernandez R, Alcocer-Varela J, Marcial D, Gomez-Martín D. Total hip arthroplasty outcomes: an 18-year experience in a single center: is systemic lupus erythematosus a potential risk factor for adverse outcomes? *J Arthroplasty.* 2017;32:3462–7.
91. Kang Y, Zhang ZJ, Zhao XY, Zhang ZQ, Sheng PY, Liao WM. Total hip arthroplasty for vascular necrosis of the femoral head in patients with systemic lupus erythematosus: a midterm follow-up study of 28 hips in 24 patients. *Eur J Orthop Surg Traumatol.* 2013;23:73–9.
92. Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. *Pharmacotherapy.* 2005;25:1566–91.
93. Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. *JAMA.* 2002;287:236–40.
94. Robinson KL, Marasco SF, Street AM. Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Part two: Transfusion issues. *Heart Lung Circ.* 2002;11:42–51.
95. Buerke M, Hoffmeister HM. Management of NOAK administration during invasive of surgical interventions: when and how to pause and when to restart. *Med Klin Intensivmed Notfmed.* 2017;112:105–10.
96. Bissar L, Almoallim H, Albazli K, Alotaibi M, Alwafi S. Perioperative management of patients with rheumatic diseases. *Open Rheumatol J.* 2013;7:42–50.
97. Akkara Veetil BM, Bongartz T. Perioperative care for patients with rheumatic diseases. *Nat Rev Rheumatol.* 2011;8:32–41.
98. Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. *Arthritis Rheumatol.* 2017;69:1538–51.
99. Chen YW, Chang JK, Huang KY, Lin GT, Lin SY, Huang CY. Hip arthroplasty for osteonecrosis in patients with systemic lupus erythematosus. *Kaohsiung J Med Sci.* 1999;15:697–703.
100. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolatemofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol.* 2009;20:1103–12.
101. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. *Rheumatology (Oxford).* 2010;49:128–40.
102. Arévalo-Martínez FG, Andrade-Ortega L, Irazoque-Palazuelos F, Badía-Flores JJ. Presentación atípica y evolución clínica de la nefropatía lúpica mesangial. Estudio de 20 pacientes. *Reumatol Clin.* 2006;2:4–9.
103. Bertias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. *Ann Rheum Dis.* 2012;71:1771–82.
104. Collado MV, Dorado E, Rausch S, Gomez G, Khoury M, Zazzetti F, et al. Long-term outcome of lupus nephritis class II in Argentine patients. An open retrospective analysis. *J Clin Rheumatol.* 2016;22:299–306.
105. Liu L, Jiang Y, Wang L, Yao L, Li Z. Efficacy and safety of mycophenolatemofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. *Drugs.* 2012;72:1521–33.
106. Arends S, Berden JH, Grootsholten C, Derksen RH, Berger SP, de Slévaux RG, et al. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolatemofetil in proliferative lupus nephritis. *Neth J Med.* 2014;72:481–90.
107. Tian S, Feldman B, Beyene J, Brown P, Uleryk E, Silverman E. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. *J Rheumatol.* 2014;41:1998–2007.
108. Singh JA, Hossain A, Kotb A, Oliveira A, Mudano AS, Grossman J, et al. Treatments for lupus nephritis: a systematic review and network metaanalysis. *J Rheumatol.* 2016;43:1801–15.
109. Grootsholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. *Kidney Int.* 2006;70:732–42.
110. Ikeuchi H, Hiromura K, Takahashi S, Mishima K, Sakurai N, Sakairi T, et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolatemofetil and a steroid in patients with active lupus nephritis. *Mod Rheumatol.* 2014;24:618–25.
111. Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. *Rheumatology (Oxford).* 2014;53:1570–7.
112. Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. *Ann Intern Med.* 2015;162:18–26.
113. Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, et al. Tacrolimus versus mycophenolatemofetil for induction therapy of lupus nephritis: a randomized controlled trial and long-term follow-up. *Ann Rheum Dis.* 2016;75:30–6.
114. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N Engl J Med.* 2005;353:2219–28.
115. Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. *Nephrol Dial Transplant.* 2012;27:1467–72.
116. Yap DY, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM. Long-term data on tacrolimus treatment in lupus nephritis. *Rheumatology (Oxford).* 2014;53:2232–7.
117. Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. *Ann Rheum Dis.* 2013;72:1280–6.
118. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. *Ann Rheum Dis.* 2010;69:61–4.
119. Sahin GM, Sahin S, Kiziltas S, Masatlioglu S, Oguz F, Ergin H. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis. *Ren Fail.* 2008;30:865–9.
120. Tang Z, Wang Z, Zhang HT, Hu WX, Zeng CH, Chen HP, et al. Clinical features and renal outcome in lupus patients with diffuse crescentic glomerulonephritis. *Rheumatol Int.* 2009;30:45–9.
121. Chen S, Chen H, Liu Z, Zhang H, Hu W, Tang Z, et al. Pathological spectrums and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis. *Rheumatol Int.* 2015;35:709–17.
122. Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. *Lupus.* 2013;22:574–82.
123. Manou-Stathopoulou S, Robson MG. Risk of clinical deterioration in patients with lupus nephritis receiving rituximab. *Lupus.* 2016;25:1299–306.
124. Mochizuki K, Kayakabe K, Hiromura K, Ando M, Sakurai N, Ikeuchi H, et al. Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolatemofetil. *CEN Case Rep.* 2015;4:126–30.
125. Ruiz Irastorza G, Espinosa G, Frutos MA, Jiménez Alonso J, Praga M, Pallarés L, et al. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (SEN). *Nefrologia.* 2012;32:1–35.
126. Kitamura N, Matsukawa Y, Takei M, Sawada S. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis. *J Int Med Re.* 2009;37:892–8.
127. Cortés-Hernández J, Ordi-Ros J, Labrador M, Segarra A, Tovar JL, Balada E, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. *Lupus.* 2003;12:287–96.
128. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. *Lupus.* 2006;15:366–70.
129. Pons-Estel GJ, Alarcón GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. *Arthritis Rheum.* 2009;61:830–9.
130. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolatemofetil or pulse cyclophosphamide. *Arthritis Care Res (Hoboken).* 2011;63:351–7.
131. Chong YB, Yap DY, Tang CS, Chan TM. Dyslipidaemia in patients with lupus nephritis. *Nephrology (Carlton).* 2011;16:511–7.
132. Wilhelmus S, Bajema IM, Bertias GK, Boumpas DT, Gordon C, Lightstone L, et al. Lupus nephritis management guidelines compared. *Nephrol Dial Transplant.* 2016;31:904–13.
133. Kang SH, Chung BH, Choi SR, Lee JY, Park HS, Sun IO, et al. Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. *Korean J Intern Med.* 2011;26:60–7.
134. Weng CH, Hsu CW, Yu CC, Yen TH, Yang CW, Hung CC. Peritoneal dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes. *Kidney Blood Press Res.* 2009;32:451–6.
135. Stanhope TJ, White WM, Moder KG, Smyth A, Garovic VD. Obstetric nephrology: lupus and lupus nephritis in pregnancy. *Clin J Am Soc Nephrol.* 2012;7:2089–99.
136. Kattah AG, Garovic VC. Pregnancy and lupus nephritis. *Semin Nefrol.* 2015;35:487–99.
137. Bramham K, Soh MC, Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. *Lupus.* 2012;21:1271–83.
138. Imazio M. Pericardial involvement in systemic inflammatory diseases. *Heart.* 2011;97:1882–92.
139. Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. *Lupus.* 2005;14:822–6.
140. Artom G, Koren-Morag N, Spodick DH, Brucato A, Guindo J, Bayes-de-Luna A, et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. *Eur Heart J.* 2005;26:723–7.
141. Imazio M, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, et al. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. *Circulation.* 2008;118:667–71.

142. Haute Autorité de Santé (HAS). Available from: [https://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/ald.21\\_lap\\_lupus\\_web.pdf](https://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/ald.21_lap_lupus_web.pdf) [accessed 21.12.2017].
143. Kruzliak P, Novak M, Piler P, Kovacova G. Pericardial involvement in systemic lupus erythematosus: current diagnosis and therapy. *Acta Cardiol.* 2013;68:629–33.
144. Morel N, Bonjour M, Le Guern V, Le Jeune C, Mouthon L, Piette JC, et al. Colchicine: a simple and effective treatment for pericarditis in SLE? A report for ten cases. *Lupus.* 2015;24:1479–85.
145. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. *Lancet.* 2014;383:2232–7.
146. Thomas G, Cohen Aubart F, Chiche L, Haroche J, Hié M, Hervier B, et al. The lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients. *J Rheumatol.* 2017;44:24–32.
147. García MA, Alarcón GS, Boggio G, Hachuel L, Marcos AI, Marcos JC, et al. Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors. Data from a multi-ethnic Latin American cohort. *Rheumatology (Oxford).* 2014;53:1431–8.
148. Gonzalez-Lopez L, Cardona-Muñoz EG, Celis A, García-de la Torre I, Orozco-Barocio G, Salazar-Paramo M, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. *Lupus.* 2004;13:105–12.
149. Kommireddy S, Bhyravajhala S, Kurimeti K, Chennareddy S, Kanchinadham S, Rajendra Vara Prasad I, et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. *Rheumatology (Oxford).* 2015;54:1673–9.
150. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani M. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. *J Rheumatol.* 2002;29:282–7.
151. Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inanç M, et al. Treatment algorithms in systemic lupus erythematosus. *Arthritis Care Res (Hoboken).* 2015;67:1237–45.
152. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, Ishii T, Satoh K, Miura Y, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. *Circ J.* 2011;75:2668–74.
153. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPCC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J.* 2015;46:903–75.
154. Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hypertension: a meta-analysis. *Cardiology.* 2011;120:157–65.
155. Robbins IM, Gaine SP, Schilz R, Tapson VE, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. *Chest.* 2000;117:14–8.
156. Shirai Y, Yasuoka H, Takeuchi T, Satoh T, Kuwana M. Intravenous poprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single centre. *Mod Rheumatol.* 2013;23:1211–20.
157. Oudiz RJ, Schilz RJ, Barst RJ, Galiè N, Rich S, Rubin LJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. *Chest.* 2004;126:420–7.
158. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. *Circulation.* 2009;119:2894–903.
159. Beltrán-Gómez ME, Sandoval-Zárate J, Pulido T. Inhibidores de fosfodiesterasa-5 para el tratamiento de la hipertensión arterial pulmonar. *Arch Cardiol Mex.* 2015;85:215–24.
160. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, et al. Sildenafil for pulmonary arterial. Hypertension associated with connective tissue diseases. *J Rheumatol.* 2007;34:2417–22.
161. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med.* 2002;346:896–903.
162. Keane MP, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. *Thorax.* 2000;55:159–66.
163. Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. *Best Pract Res Clin Rheumatol.* 2009;23:469–80.
164. Matthay RA, Schwarz MI, Petty TL, Stanford RE, Gupta RC, Sahn SA, et al. Pulmonary manifestations of lupus erythematosus: review of twelve cases of acute lupus pneumonitis. *Medicine (Baltimore).* 1975;54:397–409.
165. Allen D, Fischer A, Bshouty Z, Robinson DB, Peschken CA, Hitchon C, et al. Evaluating systemic lupus erythematosus patients for lung involvement. *Lupus.* 2012;21:1316–25.
166. Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. *Semin Arthritis Rheum.* 1990;20:48–56.
167. Okada M, Suzuki K, Matsumoto M, Nakashima M, Nakanishi T, Takada K, et al. Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases. *Mod Rheumatol.* 2007;17:131–6.
168. Badsha H, Teh CL, Kong KO, Lian TY, Chng HH. Pulmonary hemorrhage in systemic lupus erythematosus. *Semin Arthritis Rheum.* 2004;33:414–21.
169. Andrade C, Mendonça T, Farinha F, Correia J, Marinho A, Almeida I, et al. Alveolar hemorrhage in systemic lupus erythematosus: a cohort review. *Lupus.* 2016;25:75–80.
170. Schwab EP, Schumacher HR Jr, Freundlich B, Callegari PE. Pulmonary alveolar hemorrhage in systemic lupus erythematosus. *Semin Arthritis Rheum.* 1993;23:8–15.
171. Tse JR, Schwab KE, McMahon M, Simon W. Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus. *Lupus.* 2015;24:756–9.
172. Alabed IB. Treatment of diffuse alveolar hemorrhage in systemic lupus erythematosus patient with local pulmonary administration of factor VIIa (rFVIIa): a case report. *Medicine (Baltimore).* 2014;93:e72.
173. Fong KY, Thumboo J. Neuropsychiatric lupus: clinical challenges, brain-reactive autoantibodies and treatment strategies. *Lupus.* 2010;19:1399–403.
174. McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. *Neurology.* 2005;64:297–303.
175. Bertias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. *Ann Rheum Dis.* 2010;69:2074–82.
176. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. *Ann Rheum Dis.* 2005;64:620–5.
177. Saison J, Costedoat-Chalumeau N, Maucourt-Boulch D, Iwaz J, Marignier R, Cacoub P, et al. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. *Lupus.* 2015;24:74–81.
178. Espinosa G, Mendizábal A, Mínguez S, Ramo-Tello C, Capellades J, Olivé A, et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. *Semin Arthritis Rheum.* 2010;39:246–56.
179. Lin YC, Wang AG, Yen MY. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. *Acta Ophthalmol.* 2009;87:204–10.
180. Levy Y, Uziel Y, Zandman GG, Amital H, Sherer Y, Langevitz P, et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. *Ann Rheum Dis.* 2003;62:1221–3.
181. Vina ER, Fang AJ, Wallace DJ, Weisman MH. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. *Semin Arthritis Rheum.* 2005;35:175–84.
182. Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus: a systematic review. *Int J Rheum Dis.* 2014;17:494–501.
183. Dale RC, Yin K, Ding A, Merheb V, Varadkhar S, McKay D, et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. *Dev Med Child Neurol.* 2010;53:522–8.
184. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. *Drugs.* 2016;76:459–83.
185. Orzechowski NM, Wolanskyj AP, Ahlskog JE, Kumar N, Moder KG. Antiphospholipid antibody associated chorea. *J Rheumatol.* 2008;35:2165–70.
186. Peluso S, Antenora A, de Rosa A, Roca A, Maddaluno G, Brescia Morra V, et al. Antiphospholipid-related chorea. *Front Neurol.* 2012;3:150.
187. Binstadt BA, Caldas AM, Turvey SE, Stone KD, Weinstein HJ, Jackson J, et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. *J Pediatr.* 2003;143:598–604.
188. Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. *Am J Med.* 2003;115:59–62.
189. Lim LS, Lefebvre A, Benseler S, Silverman ED. Longterm outcomes and damage accrual in patients with childhood systemic lupus erythematosus with psychosis and severe cognitive dysfunction. *J Rheumatol.* 2013;40:513–9.
190. Arnal C, Piette JC, Léone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. *J Rheumatol.* 2002;29:75–83.
191. Eyanson S, Passo MH, Aldo-Benson MA, Benson MD. Methylprednisolone pulse therapy for nonrenal lupus erythematosus. *Ann Rheum Dis.* 1980;39:377–80.
192. Lurie DP, Kahaleh MB. Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus. *J Rheumatol.* 1982;9:311–4.
193. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. *Blood.* 2017;129:2829–35.
194. Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. *Arthritis Rheum.* 1990;33:1233–9.
195. Ter Borg EJ, Kallenberg CG. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin. *Ann Rheum Dis.* 1992;51:1149–51.
196. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. *Clin Rev Allergy Immunol.* 2005;29:219–28.



197. Letchumanan P, Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. *Semin Arthritis Rheum.* 2011;40:298–306.
198. West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. *Ann Intern Med.* 1988;108:703–6.
199. Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA, et al. Haematological manifestations of lupus. *Lupus Sci Med.* 2015;2:e000078.
200. Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarew M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. *J Rheumatol.* 2008;35:826–33.
201. Chen H, Zheng W, Su J, Xu D, Wang Q, Leng X, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus: a prospective pilot study. *Rheumatology (Oxford).* 2011;50:1640–4.
202. Coon WW. Splenectomy for cytopenias associated with systemic lupus erythematosus. *Am J Surg.* 1988;155:391–4.
203. Rivero SJ, Alger M, Alarcón-Segovia D. Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal. *Arch Intern Med.* 1979;139:773–6.
204. Hsu CY, Chen HJ, Hsu CY, Kao CH. Splenectomy increases the subsequent risk of systemic lupus erythematosus. *Rheumatol Int.* 2016;36:271–6.
205. You YN, Tefferi A, Nagorner DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. *Ann Surg.* 2004;240:286–92.
206. Roach BA, Hutchinson GJ. Treatment of refractory, systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide. *Arthritis Rheum.* 1993;36:682–4.
207. Boumpas DT, Barez S, Klippel JH, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. *Ann Intern Med.* 1990;112:674–7.
208. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. *Lupus.* 2001;10:154–61.
209. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. *Lupus.* 2003;12:630–2.
210. Goebel KM, Gassel WD, Goebel FD. Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. *Scand J Haematol.* 1973;10:28–34.
211. Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. *Lupus.* 2001;10:152–3.
212. Maroun MC, Osofski R, Andersen JC, Dhar JP. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus. *Lupus.* 2015;24:746–50.
213. Scheinberg P, Singulane CC, Barbosa LS, Scheinberg M. Successful plateletcount recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. *Clin Rheumatol.* 2014;33:1347–9.
214. Estcourt LJ, Birchall J, Allard S, Bassej SJ, Hersey P, Kerr JP, et al. Guidelines for the use of platelet transfusions. *Br J Haematol.* 2017;176:365–94.
215. Tokunaga M, Fujii K, Saito K, Nakayama S, Tsujimura S, Nawata M, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. *Rheumatology (Oxford).* 2005;44:176–82.
216. Barcellona W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. *Blood.* 2012;119:3691–7.
217. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. *Br J Haematol.* 2002;116:465–7.
218. Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. *Blood.* 2015;125:3223–9.
219. Abdwani R, Mani R. Anti-CD20 monoclonal antibody in acute life threatening hemolytic anaemia complicating childhood onset SLE. *Lupus.* 2009;18:460–4.
220. Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune hemolytic anaemia. *Br J Haematol.* 2013;163:393–9.
221. Meyer O, Stahl D, Beckhove P, Huhn D, Salama A. Pulsed high-dose dexamethasone in chronic autoimmune hemolytic anaemia of warm type. *Br J Haematol.* 1997;98:860–2.
222. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. *Blood.* 2017;129:2971–9.
223. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. *Am J Med.* 2000;108:198–204.
224. Corley CC Jr, Lessner HE, Larsen WE. Azathioprine therapy of “autoimmune” diseases. *Am J Med.* 1966;41:404–12.
225. Ahn YS, Harrington WJ, Mylvaganam R, Ayub J, Pall LM. Danazol therapy for autoimmune hemolytic anemia. *Ann Intern Med.* 1985;102:298–301.
226. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Sanchez-Andrade A, González-Gay MA. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. *Br J Rheumatol.* 1997;36:1095–9.
227. Chan AC, Sack K. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus. *J Rheumatol.* 1991;18:280–2.
228. Watad A, Amital H, Shoenfeld Y. Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions. *Lupus.* 2017;26:1015–22.
229. Watad A, Mok CC. Mycophenolate mofetil for refractory hemolytic anemia in systemic lupus erythematosus. *Lupus.* 2005;14:856–8.
230. Tselios K, Gladman DD, Su J, Urowitz MB. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. *J Rheumatol.* 2016;43:552–8.
231. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune hemolytic anaemia and auto-immune thrombocytopenia purpura. *Br J Haematol.* 2002;117:712–5.
232. Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. *Blood.* 2002;100:704–6.
233. Misra DP, Jain VK, Negi VS. Splenectomy increases the subsequent risk of systemic lupus erythematosus: a word of caution. *Rheumatol Int.* 2016;36:277–8.
234. Buetens OW, Ness PM. Red blood cell transfusion in autoimmune hemolytic anemia. *Curr Opin Hematol.* 2003;10:429–33.
235. Levine AB, Erkan D. Clinical assessment and management of cytopenias in lupus patients. *Curr Rheumatol Rep.* 2011;13:291–9.
236. Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus—old and new. *Autoimmun Rev.* 2013;12:784–91.
237. Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. *J Rheumatol.* 1997;24:2153–7.
238. Vasiliu IM, Petri MA, Baer AN. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flare. *J Rheumatol.* 2006;33:1878–80.
239. Euler HH, Schwab UM, Schroeder JO. Filgrastim for lupus neutropenia. *Lancet.* 1994;344:1513–4.
240. Newman KA, Akhtari M. Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus. *Autoimmun Rev.* 2011;10:432–7.
241. Abu-Hishmeh M, Sattar A, Zarlasht F, Ramadan M, Abdel-Rahman A, Hinson S, et al. Systemic lupus erythematosus presenting as refractory thrombotic thrombocytopenic purpura: a diagnostic and management challenge. A case report and concise review of the literature. *Am J Case Rep.* 2016;17:782–878.
242. Hamasaki K, Mimura T, Kanda H, Kubo K, Setoguchi K, Satoh T, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. *Clin Rheumatol.* 2003;22:355–8.
243. Jiang H, An X, Li Y, Sun Y, Shen G, Tu Y, et al. Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011. *Clin Rheumatol.* 2014;33:419–27.
244. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. *Br J Haematol.* 2012;158:323–35.
245. Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. *Transfusion.* 2005;45:41–9.
246. Atteritano M, David A, Bagnato G, Beninati C, Frisina A, Iaria C, et al. Haemophagocytic syndrome in rheumatic patients. A systematic review. *Eur Rev Med Pharmacol Sci.* 2012;16:1414–24.
247. Xu N, Zhao J, Liu J, Wu D, Zhao L, Wang Q, et al. Clinical analysis of 61 systemic lupus erythematosus patients with intestinal pseudo-obstruction and/or ureterohydronephrosis. *Medicine (Baltimore).* 2015;94:e419.
248. García López CA, Laredo-Sánchez F, Malagón-Rangel J, Flores-Padilla MG, Nellen-Hummel H. Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge. *World J Gastroenterol.* 2014;20:11443–50.
249. Jin P, Ji X, Zhi H, Song X, Du H, Zhang K, et al. A review of 42 cases of intestinal pseudo-obstruction in patients with systemic lupus erythematosus based on case reports. *Hum Immunol.* 2015;76:695–700.
250. Wang Q, Shen M, Leng X, Zeng X, Zhang F, Qian J. Prevalence, severity, and clinical features of acute and chronic pancreatitis in patients with systemic lupus erythematosus. *Rheumatol Int.* 2016;36:1413–9.
251. Yang Y, Ye Y, Liang L, Wu T, Zhan Z, Yang X, et al. Systemic-lupus-erythematosus-related acute pancreatitis: a cohort from South China. *Clin Dev Immunol.* 2012;2012:568564.
252. Yu YK, Yu F, Ye C, Dai YJ, Huang XW, Hu SX. Retrospective analysis of plasma exchange combined with glucocorticosteroids for the treatment of systemic lupus erythematosus-related acute pancreatitis in Central China. *J Huazhong Univ Sci Technol Med Sci.* 2016;36:501–8.
253. Chen Z, Li MT, Xu D, Yang H, Li J, Zhao JL, et al. Protein-losing enteropathy in systemic lupus erythematosus: 12 years experience from a Chinese academic center. *PLoS One.* 2014;9:e114684.

254. Zheng WJ, Tian XP, Li L, Jing HL, Li F, Zeng XF, et al. Protein-losing enteropathy in systemic lupus erythematosus analysis of the clinical features of fifteen patients. *J Clin Rheumatol.* 2007;13:313–6.
255. Law ST, Ma KM, Li KK. The clinical characteristics of lupus related protein-losing enteropathy in Hong Kong Chinese population: 10 years of experience from a regional hospital. *Lupus.* 2012;21:840–7.
256. Janssens P, Arnaud L, Galicier L, Mathian A, Hie M, Sene D, et al. Lupus enteritis: From clinical findings to therapeutic management. *Orphanet J Rare Dis.* 2013;8:67.
257. Yuan S, Ye Y, Chen D, Qiu Q, Zhan Z, Lian F, et al. Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease. *Semin Arthritis Rheum.* 2014;43:759–66.
258. Huang DF, Chen WS. Images in clinical medicine. Lupus-associated intestinal vasculitis. *N Engl J Med.* 2009;361:e3.
259. Macías-Parra M. *Inmunizaciones.* 2nd ed. México, DF: Editorial McGraw-Hill Interamericana; 2001. p. 5–31.